

# John J V McMurray

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5419095/publications.pdf>

Version: 2024-02-01

1,257  
papers

220,319  
citations

45

186  
h-index

27

438  
g-index

1315  
all docs

1315  
docs citations

1315  
times ranked

93576  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.   | 27.0 | 7,537     |
| 2  | 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2013, 62, e147-e239.  | 2.8  | 7,017     |
| 3  | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.   | 2.2  | 5,689     |
| 4  | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.  | 2.2  | 5,558     |
| 5  | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1665-1701. | 2.2  | 5,247     |
| 6  | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.  | 2.2  | 5,233     |
| 7  | Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine, 2014, 371, 993-1004.  | 27.0 | 5,052     |
| 8  | Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2369-2429.  | 2.2  | 4,635     |
| 9  | Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.  | 27.0 | 4,108     |
| 10 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.   | 1.7  | 3,523     |
| 11 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.  | 1.6  | 2,807     |
| 12 | ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.   | 2.2  | 2,767     |
| 13 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 2008, 29, 2388-2442.  | 2.2  | 2,656     |
| 14 | Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, The, 2003, 362, 777-781.   | 13.7 | 2,584     |
| 15 | Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 2020, 383, 1436-1446.   | 27.0 | 2,523     |
| 16 | Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 2011, 364, 11-21.  | 27.0 | 2,491     |
| 17 | 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.  | 1.6  | 2,335     |
| 18 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.   | 7.1  | 2,307     |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine, 2003, 349, 1893-1906.  | 27.0 | 2,240     |
| 20 | A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2009, 361, 2019-2032.   | 27.0 | 2,110     |
| 21 | Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, The, 2010, 375, 735-742.  | 13.7 | 2,064     |
| 22 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, The, 2003, 362, 767-771.   | 13.7 | 1,978     |
| 23 | Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. New England Journal of Medicine, 2005, 352, 1071-1080.   | 27.0 | 1,950     |
| 24 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Journal of Heart Failure, 2008, 10, 933-989.   | 7.1  | 1,893     |
| 25 | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine, 2015, 373, 2247-2257.   | 27.0 | 1,856     |
| 26 | Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. European Heart Journal, 2006, 28, 230-268.  | 2.2  | 1,802     |
| 27 | Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 367, 2089-2099.  | 27.0 | 1,754     |
| 28 | Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, The, 2003, 362, 759-766.   | 13.7 | 1,752     |
| 29 | Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine, 2020, 382, 1653-1659.   | 27.0 | 1,732     |
| 30 | Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal of Medicine, 2004, 351, 1285-1295.  | 27.0 | 1,712     |
| 31 | Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine, 2008, 359, 2456-2467.   | 27.0 | 1,663     |
| 32 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, The, 2003, 362, 772-776.  | 13.7 | 1,623     |
| 33 | Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.   | 27.0 | 1,485     |
| 34 | ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2851-2906. | 2.2  | 1,394     |
| 35 | Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.  | 1.7  | 1,360     |
| 36 | Rosuvastatin in Older Patients with Systolic Heart Failure. New England Journal of Medicine, 2007, 357, 2248-2261.  | 27.0 | 1,330     |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. American Journal of Medicine, 2002, 113, 359-364.  | 1.5  | 1,328     |
| 38 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, The, 2009, 373, 2125-2135.   | 13.7 | 1,243     |
| 39 | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.                                 | 13.7 | 1,179     |
| 40 | Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. New England Journal of Medicine, 2012, 367, 2204-2213.  | 27.0 | 1,145     |
| 41 | Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 2011, 365, 32-43.   | 27.0 | 1,133     |
| 42 | Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. Circulation, 2004, 109, 1594-1602.  | 1.6  | 1,062     |
| 43 | The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, The, 2012, 380, 1387-1395.  | 13.7 | 990       |
| 44 | Biochemical detection of left-ventricular systolic dysfunction. Lancet, The, 1998, 351, 9-13.   | 13.7 | 967       |
| 45 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, the, 2019, 7, 776-785. | 11.4 | 961       |
| 46 | Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. European Heart Journal, 2013, 34, 1404-1413.   | 2.2  | 921       |
| 47 | Increased Mortality after Dronedarone Therapy for Severe Heart Failure. New England Journal of Medicine, 2008, 358, 2678-2687.  | 27.0 | 901       |
| 48 | More "malignant" than cancer? Five-year survival following a first admission for heart failure. European Journal of Heart Failure, 2001, 3, 315-322.  | 7.1  | 885       |
| 49 | Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2492-2503.  | 27.0 | 844       |
| 50 | Predictors of mortality and morbidity in patients with chronic heart failure. European Heart Journal, 2006, 27, 65-75.  | 2.2  | 822       |
| 51 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.   | 7.1  | 820       |
| 52 | Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation, 2006, 113, 671-678.   | 1.6  | 817       |
| 53 | Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. Journal of the American College of Cardiology, 2007, 50, 40-47.  | 2.8  | 809       |
| 54 | Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet, The, 2018, 391, 572-580.  | 13.7 | 808       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2010, 12, 767-778.            | 7.1  | 787       |
| 56 | Heart failure with preserved left ventricular systolic function. <i>Journal of the American College of Cardiology</i> , 2004, 43, 317-327.   | 2.8  | 756       |
| 57 | Heart failure. <i>Lancet, The</i> , 2005, 365, 1877-1889.  | 13.7 | 756       |
| 58 | 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.  | 1.4  | 754       |
| 59 | Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2012, 14, 341-343.  | 7.1  | 737       |
| 60 | Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis. <i>New England Journal of Medicine</i> , 2007, 357, 28-38.  | 27.0 | 729       |
| 61 | Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>New England Journal of Medicine</i> , 2005, 352, 2581-2588.   | 27.0 | 721       |
| 62 | Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. <i>Circulation</i> , 2005, 112, 3738-3744.  | 1.6  | 678       |
| 63 | An epidemiological study of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2007, 30, 104-109.  | 6.7  | 668       |
| 64 | SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. <i>Diabetologia</i> , 2018, 61, 2108-2117.   | 6.3  | 641       |
| 65 | Obesity Is a Risk Factor for Severe COVID-19 Infection. <i>Circulation</i> , 2020, 142, 4-6.   | 1.6  | 595       |
| 66 | Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>European Journal of Heart Failure</i> , 2010, 12, 423-433. | 7.1  | 593       |
| 67 | Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 447-456.  | 2.8  | 591       |
| 68 | Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490.   | 27.0 | 588       |
| 69 | Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. <i>Lancet, The</i> , 1997, 350, 829-833.  | 13.7 | 582       |
| 70 | Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 920-926.   | 1.6  | 582       |
| 71 | Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. <i>European Journal of Heart Failure</i> , 2011, 13, 347-357.  | 7.1  | 580       |
| 72 | HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.   | 13.7 | 562       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.  | 1.6  | 552       |
| 74 | Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 1377-1385. | 2.2  | 549       |
| 75 | Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 1482-1487.   | 1.6  | 528       |
| 76 | Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. <i>International Journal of Cardiology</i> , 2013, 167, 1807-1824.  | 1.7  | 523       |
| 77 | Iron deficiency: an ominous sign in patients with systolic chronic heart failure. <i>European Heart Journal</i> , 2010, 31, 1872-1880.   | 2.2  | 515       |
| 78 | Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1997-2004.   | 2.8  | 507       |
| 79 | Randomised controlled trial of specialist nurse intervention in heart failure. <i>BMJ: British Medical Journal</i> , 2001, 323, 715-718.   | 2.3  | 477       |
| 80 | The current cost of heart failure to the National Health Service in the UK. <i>European Journal of Heart Failure</i> , 2002, 4, 361-371.   | 7.1  | 471       |
| 81 | Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003. <i>Circulation</i> , 2009, 119, 515-523.  | 1.6  | 468       |
| 82 | Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , 2020, 11, 163.  | 12.8 | 466       |
| 83 | Expert consensus document on $\beta$ -adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1341-1362.  | 2.2  | 465       |
| 84 | Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.  | 27.0 | 462       |
| 85 | Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 433-443.   | 7.1  | 449       |
| 86 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 653-662.   | 11.4 | 437       |
| 87 | Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.   | 7.1  | 434       |
| 88 | Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 1146-1155.   | 27.0 | 433       |
| 89 | A Comparison of the Reproducibility and the Sensitivity to Change of Visual Analogue Scales, Borg Scales, and Likert Scales in Normal Subjects During Submaximal Exercise. <i>Chest</i> , 1999, 116, 1208-1217.  | 0.8  | 432       |
| 90 | Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1463-1476.   | 27.0 | 430       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy. Circulation, 2010, 121, 1465-1473.   | 1.6  | 429       |
| 92  | 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. European Heart Journal, 2010, 31, 2677-2687. | 2.2  | 427       |
| 93  | Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 2018, 39, 26-35.   | 2.2  | 426       |
| 94  | Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Failure, 2009, 11, 130-139.   | 7.1  | 423       |
| 95  | Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation, 2011, 124, 2491-2501.  | 1.6  | 418       |
| 96  | Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet, The, 2005, 366, 2005-2011.   | 13.7 | 410       |
| 97  | Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.  | 13.7 | 408       |
| 98  | Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 2010, 159, 331-339.   | 2.7  | 407       |
| 99  | Systolic Heart Failure. New England Journal of Medicine, 2010, 362, 228-238.   | 27.0 | 395       |
| 100 | Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116.  | 27.0 | 381       |
| 101 | Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, The, 2020, 396, 121-128.  | 13.7 | 376       |
| 102 | Anemia and Its Relationship to Clinical Outcome in Heart Failure. Circulation, 2004, 110, 149-154.   | 1.6  | 371       |
| 103 | 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.  | 1.6  | 368       |
| 104 | Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). European Journal of Heart Failure, 2013, 15, 1062-1073.                          | 7.1  | 358       |
| 105 | Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.  | 27.0 | 355       |
| 106 | Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Circulation, 2004, 110, 2618-2626.  | 1.6  | 347       |
| 107 | Dilated cardiomyopathy. Nature Reviews Disease Primers, 2019, 5, 32.   | 30.5 | 347       |
| 108 | Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. Circulation: Heart Failure, 2008, 1, 17-24.   | 3.9  | 340       |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 109 | Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.   | 7.4  | 340       |
| 110 | Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis. Diabetes, Obesity and Metabolism, 2018, 20, 479-487.  | 4.4  | 336       |
| 111 | Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2007, 9, 684-694.   | 7.1  | 335       |
| 112 | Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal, 2015, 36, 1990-1997.  | 2.2  | 335       |
| 113 | Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation, 2020, 141, 352-361.   | 1.6  | 335       |
| 114 | Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2007, 298, 2009.   | 7.4  | 330       |
| 115 | Body Mass Index and Prognosis in Patients With Chronic Heart Failure. Circulation, 2007, 116, 627-636.   | 1.6  | 328       |
| 116 | Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure, 2009, 11, 170-177.   | 7.1  | 326       |
| 117 | Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. New England Journal of Medicine, 2019, 380, 447-458.   | 27.0 | 321       |
| 118 | Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2011, 13, 115-126.   | 7.1  | 318       |
| 119 | Economics of chronic heart failure. European Journal of Heart Failure, 2001, 3, 283-291.   | 7.1  | 315       |
| 120 | Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet, The, 2004, 364, 347-354.   | 13.7 | 315       |
| 121 | Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure, 2015, 17, 544-558. | 7.1  | 315       |
| 122 | Risk Prediction in Patients With Heart Failure. JACC: Heart Failure, 2014, 2, 440-446.   | 4.1  | 303       |
| 123 | 2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace, 2010, 12, 1526-1536.   | 1.7  | 297       |
| 124 | The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet, The, 2011, 378, 676-683.  | 13.7 | 295       |
| 125 | Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 2018, 20, 1230-1239.   | 7.1  | 295       |
| 126 | Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation, 2010, 121, 1393-1405.   | 1.6  | 290       |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. <i>BMJ</i> , The, 2015, 350, h910-h910.   | 6.0  | 289       |
| 128 | Investigation Into the Sources of Superoxide in Human Blood Vessels. <i>Circulation</i> , 2000, 101, 2206-2212.   | 1.6  | 287       |
| 129 | Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 22-31.                  | 11.4 | 287       |
| 130 | Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1663-1671.   | 0.7  | 286       |
| 131 | Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. <i>Heart</i> , 2011, 97, 740-747.   | 2.9  | 282       |
| 132 | Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 119-129.                   | 7.1  | 281       |
| 133 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1495-1539.   | 2.8  | 276       |
| 134 | Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006, 152, 86-92.                  | 2.7  | 275       |
| 135 | Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 489-498.   | 4.1  | 272       |
| 136 | Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2425-2436.   | 2.8  | 271       |
| 137 | Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas. <i>Circulation</i> , 2006, 114, 1028-1035.   | 1.6  | 267       |
| 138 | Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.  | 4.1  | 267       |
| 139 | A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675. | 7.1  | 264       |
| 140 | Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1812-1822.   | 2.8  | 263       |
| 141 | Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design. <i>Journal of Cardiac Failure</i> , 1999, 5, 276-282.  | 1.7  | 260       |
| 142 | Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 843-851.  | 11.4 | 260       |
| 143 | Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .   | 3.9  | 260       |
| 144 | Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15,000 middle-aged men and women (the Renfrew-Paisley study). <i>European Heart Journal</i> , 2006, 27, 96-106.  | 2.2  | 259       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 145 | Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 333-340.                               | 11.4 | 258       |
| 146 | Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.   | 27.0 | 257       |
| 147 | Serum Soluble ST2. <i>Journal of the American College of Cardiology</i> , 2010, 55, 243-250.   | 2.8  | 256       |
| 148 | Cognitive Impairment and Heart Failure: Systematic Review and Meta-Analysis. <i>Journal of Cardiac Failure</i> , 2017, 23, 464-475.  | 1.7  | 255       |
| 149 | SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. <i>Diabetologia</i> , 2016, 59, 1333-1339.  | 6.3  | 254       |
| 150 | Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. <i>Circulation</i> , 2005, 111, 3411-3419.  | 1.6  | 251       |
| 151 | Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. <i>Journal of Cardiac Failure</i> , 2005, 11, 12-20.   | 1.7  | 250       |
| 152 | Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1454-1470.                                 | 2.2  | 249       |
| 153 | Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1598-1603.   | 2.8  | 249       |
| 154 | Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 877-886. | 11.4 | 245       |
| 155 | Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.   | 1.6  | 244       |
| 156 | Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.   | 1.6  | 244       |
| 157 | Antiarrhythmic effect of carvedilol after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005, 45, 525-530.   | 2.8  | 242       |
| 158 | Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients. <i>Circulation</i> , 2004, 110, 2180-2183.  | 1.6  | 241       |
| 159 | Albuminuria in chronic heart failure: prevalence and prognostic importance. <i>Lancet</i> , 2009, 374, 543-550.  | 13.7 | 239       |
| 160 | Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 471-482.   | 4.1  | 238       |
| 161 | Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021, 143, 516-525.   | 1.6  | 237       |
| 162 | Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2007, 115, 3111-3120.   | 1.6  | 235       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 163 | Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 986-994.  | 1.6  | 229       |
| 164 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2016, 388, 2895-2903.   | 13.7 | 229       |
| 165 | Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2008, 1, 582-591.   | 5.3  | 227       |
| 166 | Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 569-577.  | 3.9  | 219       |
| 167 | Heart failure and socioeconomic status: accumulating evidence of inequality. <i>European Journal of Heart Failure</i> , 2012, 14, 138-146.   | 7.1  | 218       |
| 168 | Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 27-35.   | 3.9  | 216       |
| 169 | Iron status in patients with chronic heart failure. <i>European Heart Journal</i> , 2013, 34, 827-834.   | 2.2  | 212       |
| 170 | Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. <i>Circulation</i> , 2005, 112, 48-53.   | 1.6  | 211       |
| 171 | 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1021-1034.   | 2.8  | 211       |
| 172 | What Works In Chronic Care Management: The Case Of Heart Failure. <i>Health Affairs</i> , 2009, 28, 179-189.   | 5.2  | 209       |
| 173 | Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1585-1593.   | 2.8  | 204       |
| 174 | Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1521-1532.  | 27.0 | 204       |
| 175 | Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. <i>European Heart Journal</i> , 2010, 31, 824-831.  | 2.2  | 203       |
| 176 | Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy. <i>Circulation: Heart Failure</i> , 2014, 7, 51-58. | 3.9  | 203       |
| 177 | Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015, 17, 925-935.  | 7.1  | 203       |
| 178 | Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. <i>Circulation</i> , 2004, 110, 1572-1578.  | 1.6  | 201       |
| 179 | Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1850-1859.                                       | 2.8  | 200       |
| 180 | Trends in hospitalization for heart failure in Scotland, 1990â€“1996. An epidemic that has reached its peak?. <i>European Heart Journal</i> , 2001, 22, 209-217.   | 2.2  | 198       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 181 | Heart Failure Care in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. PLoS Medicine, 2014, 11, e1001699.  | 8.4  | 198       |
| 182 | Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study). American Journal of Cardiology, 2008, 101, 607-612.  | 1.6  | 197       |
| 183 | Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. Circulation, 2013, 127, 2166-2176.  | 1.6  | 196       |
| 184 | Explanation for the Decline in Coronary Heart Disease Mortality Rates in Auckland, New Zealand, Between 1982 and 1993. Circulation, 2000, 102, 1511-1516.  | 1.6  | 195       |
| 185 | Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. Circulation, 2010, 122, 597-602.  | 1.6  | 195       |
| 186 | Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <sc>DELIVER</sc> trial. European Journal of Heart Failure, 2021, 23, 1217-1225.  | 7.1  | 195       |
| 187 | The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure. Archives of Internal Medicine, 2008, 168, 1699.  | 3.8  | 194       |
| 188 | Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 1096-1103.   | 7.1  | 194       |
| 189 | A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure. Journal of the American College of Cardiology, 2007, 49, 1696-1704. | 2.8  | 193       |
| 190 | Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 298-309.   | 1.6  | 193       |
| 191 | Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2020, 396, 1745-1757.  | 13.7 | 192       |
| 192 | N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2274-2284.  | 2.8  | 191       |
| 193 | Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. Journal of the American College of Cardiology, 2016, 67, 1444-1455.  | 2.8  | 191       |
| 194 | Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. European Journal of Heart Failure, 2007, 9, 83-91.  | 7.1  | 188       |
| 195 | Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 2015, 36, 2576-2584.   | 2.2  | 187       |
| 196 | Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to <sc>CHARM</sc> Preserved. European Journal of Heart Failure, 2014, 16, 33-40.  | 7.1  | 186       |
| 197 | Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet, The, 2014, 383, 1059-1066.   | 13.7 | 186       |
| 198 | Epidemiology of Heart Failure and Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Prevalence, Clinical Characteristics, and Prognostic Importance. American Journal of Cardiology, 2006, 97, 13-25.   | 1.6  | 185       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 199 | Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008, 29, 1224-1240.   | 2.2  | 184       |
| 200 | Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009, 158, 896-901.e3.   | 2.7  | 184       |
| 201 | Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 535-542.  | 7.1  | 184       |
| 202 | Heart failure in a cold climate. <i>Journal of the American College of Cardiology</i> , 2002, 39, 760-766.   | 2.8  | 183       |
| 203 | Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008, 10, 149-156.  | 7.1  | 183       |
| 204 | Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.                                   | 7.1  | 182       |
| 205 | Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 656-665.   | 5.3  | 182       |
| 206 | A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. <i>Kidney International</i> , 2021, 100, 215-224.                          | 5.2  | 182       |
| 207 | Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. <i>European Journal of Heart Failure</i> , 2017, 19, 1154-1163.                             | 7.1  | 181       |
| 208 | Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>European Journal of Heart Failure</i> , 2016, 18, 1193-1202.                  | 7.1  | 180       |
| 209 | Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 371, 1761-1768.  | 13.7 | 178       |
| 210 | Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .  | 3.9  | 178       |
| 211 | Seasonal variations in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 654-664.   | 13.7 | 178       |
| 212 | The Lys198Asn Polymorphism in the Endothelin-1 Gene Is Associated With Blood Pressure in Overweight People. <i>Hypertension</i> , 1999, 33, 1169-1174.   | 2.7  | 177       |
| 213 | Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 571-578.   | 3.9  | 177       |
| 214 | Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1749-1758. | 13.7 | 175       |
| 215 | Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1228-1234.                    | 7.1  | 173       |
| 216 | Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 795-806.   | 2.8  | 173       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 217 | Selecting patients for cardiac resynchronization therapy: electrical or mechanical dyssynchrony?. European Heart Journal, 2006, 27, 1270-1281.   | 2.2  | 170       |
| 218 | Predominance of Heart Failure in the Heart of Soweto Study Cohort. Circulation, 2008, 118, 2360-2367.  | 1.6  | 168       |
| 219 | Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. Journal of the American College of Cardiology, 2019, 73, 29-40.  | 2.8  | 168       |
| 220 | Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation, 2020, 35, 274-282.   | 0.7  | 168       |
| 221 | Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. European Heart Journal, 1998, 19, 481-489.  | 2.2  | 167       |
| 222 | Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. European Journal of Heart Failure, 2012, 14, 473-479.  | 7.1  | 167       |
| 223 | Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 2008, 29, 2641-2650.                          | 2.2  | 164       |
| 224 | Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal, 2000, 140, 727-750.  | 2.7  | 162       |
| 225 | Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143. | 2.2  | 160       |
| 226 | The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European Journal of Heart Failure, 2019, 21, 1402-1411.   | 7.1  | 159       |
| 227 | What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?. Journal of the American College of Cardiology, 2012, 60, 2349-2356.   | 2.8  | 157       |
| 228 | Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2014, 2, 116-124.   | 11.4 | 157       |
| 229 | Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. American Heart Journal, 2011, 162, 938-948.e2.  | 2.7  | 156       |
| 230 | Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation, 2009, 120, 2188-2196.                                       | 1.6  | 155       |
| 231 | The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. International Journal of Obesity, 2014, 38, 1110-1114.  | 3.4  | 155       |
| 232 | Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.                | 13.7 | 155       |
| 233 | A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart, 2007, 93, 606-612.  | 2.9  | 154       |
| 234 | Incidence and Predictors of Hyperkalemia in Patients With Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1959-1966.   | 2.8  | 153       |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 235 | Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 510-517.  | 7.1 | 153       |
| 236 | Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. Circulation, 2017, 135, 724-735.  | 1.6 | 153       |
| 237 | 2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure, 2010, 12, 1143-1153.   | 7.1 | 152       |
| 238 | Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 2020, 41, 2379-2392.   | 2.2 | 151       |
| 239 | Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. European Heart Journal, 2007, 28, 829-835.  | 2.2 | 150       |
| 240 | Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation: Heart Failure, 2017, 10, .   | 3.9 | 150       |
| 241 | The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2006, 47, 726-733.  | 2.8 | 149       |
| 242 | Results of a reevaluation of cardiovascular outcomes in the RECORD trial. American Heart Journal, 2013, 166, 240-249.e1.  | 2.7 | 149       |
| 243 | How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?. Circulation, 2021, 143, 875-877.  | 1.6 | 149       |
| 244 | Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal, 2012, 33, 2782-2795.  | 2.2 | 148       |
| 245 | Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGM-HF</scp>). European Journal of Heart Failure, 2014, 16, 817-825. | 7.1 | 148       |
| 246 | Vasodilator Effects of Endothelin-Converting Enzyme Inhibition and Endothelin ET A Receptor Blockade in Chronic Heart Failure Patients Treated With ACE Inhibitors. Circulation, 1996, 94, 2131-2137.   | 1.6 | 148       |
| 247 | Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 1785-1795.  | 2.8 | 146       |
| 248 | Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation, 2018, 138, 1505-1514.   | 1.6 | 145       |
| 249 | Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, 2020, 141, 100-111.   | 1.6 | 145       |
| 250 | Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 2012, 33, 2290-2296.   | 2.2 | 144       |
| 251 | Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2011, 162, 900-906.                            | 2.7 | 143       |
| 252 | Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. JAMA Cardiology, 2017, 2, 79.  | 6.1 | 143       |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 253 | Failure of Women's Hearts. <i>Circulation</i> , 1999, 99, 2334-2341.   | 1.6  | 142       |
| 254 | Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. <i>Circulation</i> , 2016, 133, 2254-2262.  | 1.6  | 142       |
| 255 | Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 271-277.  | 2.7  | 141       |
| 256 | Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [ <i>Eur Heart J</i> 2008;29:2388-2442]. <i>European Heart Journal</i> , 2010, 31, 624-624. | 2.2  | 141       |
| 257 | Lipid-Modifying Therapies and Risk of Pancreatitis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 804.  | 7.4  | 140       |
| 258 | Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 224-232.   | 2.2  | 140       |
| 259 | Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 8-17.   | 4.1  | 140       |
| 260 | Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. <i>Journal of Cardiac Failure</i> , 2014, 20, 953-958.  | 1.7  | 139       |
| 261 | The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. <i>Heart</i> , 2016, 102, 1342-1347.   | 2.9  | 139       |
| 262 | Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. <i>Circulation</i> , 2018, 138, 2774-2786.  | 1.6  | 139       |
| 263 | B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1264-1272.   | 2.8  | 139       |
| 264 | Echocardiography and lung ultrasonography for the assessment and management of acute heart failure. <i>Nature Reviews Cardiology</i> , 2017, 14, 427-440.  | 13.7 | 138       |
| 265 | Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2858-2873.  | 2.8  | 138       |
| 266 | Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. <i>European Heart Journal</i> , 2001, 22, 693-701.   | 2.2  | 137       |
| 267 | Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2013, 6, 451-460.   | 3.9  | 136       |
| 268 | Heart Failure and Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2127-2138.   | 2.8  | 135       |
| 269 | The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition. <i>JAMA Cardiology</i> , 2017, 2, 939.  | 6.1  | 135       |
| 270 | Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. <i>Kidney International</i> , 2000, 57, 1100-1106.  | 5.2  | 134       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 271 | Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.   | 3.9  | 134       |
| 272 | High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 52-61.   | 2.8  | 133       |
| 273 | Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1990, 65, 1261-1262.   | 1.6  | 132       |
| 274 | Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 38, 729-735.  | 2.8  | 130       |
| 275 | Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011, 32, 1227-1234.   | 2.2  | 130       |
| 276 | Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 666.  | 6.1  | 130       |
| 277 | Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002744.  | 3.9  | 130       |
| 278 | Angiotensin Receptorâ€“Neprilysin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.  | 27.0 | 130       |
| 279 | The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design. <i>Journal of Cardiac Failure</i> , 2005, 11, 576-585.  | 1.7  | 129       |
| 280 | Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGMâ€“HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 337-341.  | 7.1  | 129       |
| 281 | New Therapeutic Options in Congestive Heart Failure: Part I. <i>Circulation</i> , 2002, 105, 2099-2106.  | 1.6  | 128       |
| 282 | Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case-Control Study From the U.K. General Practice Research Database. <i>Diabetes Care</i> , 2010, 33, 1213-1218.  | 8.6  | 128       |
| 283 | Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.   | 1.6  | 128       |
| 284 | A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2005, 7, 1059-1069.   | 7.1  | 127       |
| 285 | An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2004, 25, 1911-1919.   | 2.2  | 126       |
| 286 | The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.   | 2.2  | 126       |
| 287 | Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021, 42, 3727-3738.  | 2.2  | 125       |
| 288 | Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 547-554. | 11.4 | 124       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 289 | Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD. <i>American Journal of Kidney Diseases</i> , 2011, 58, 717-728.  | 1.9 | 123       |
| 290 | Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2013, 1, 21-28.  | 4.1 | 123       |
| 291 | Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 590-595.  | 3.9 | 123       |
| 292 | Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1056-1061.   | 2.8 | 122       |
| 293 | Statins and chronic heart failure: do we need a large-scale outcome trial?. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1567-1573.   | 2.8 | 122       |
| 294 | Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-II, high-sensitivity C-reactive peptide and N-terminal pro-B-type natriuretic peptide. <i>European Journal of Heart Failure</i> , 2009, 11, 281-291.           | 7.1 | 120       |
| 295 | Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 499.   | 6.1 | 120       |
| 296 | Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2003, 5, 261-270. | 7.1 | 119       |
| 297 | Public awareness of heart failure in Europe: first results from SHAPE. <i>European Heart Journal</i> , 2005, 26, 2413-2421.   | 2.2 | 118       |
| 298 | Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2059-2071.  | 2.8 | 118       |
| 299 | Impaired endothelial function in isolated human uremic resistance arteries. <i>Kidney International</i> , 2001, 60, 1077-1082.  | 5.2 | 117       |
| 300 | Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. <i>European Heart Journal</i> , 2008, 30, 56-65.  | 2.2 | 117       |
| 301 | Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.   | 3.9 | 117       |
| 302 | Lung Ultrasound in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 849-858.  | 4.1 | 116       |
| 303 | Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. <i>American Heart Journal</i> , 2005, 149, 408-413.   | 2.7 | 115       |
| 304 | The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. <i>European Journal of Heart Failure</i> , 2009, 11, 855-862.   | 7.1 | 114       |
| 305 | Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.  | 2.2 | 114       |
| 306 | Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2490-2500.  | 2.8 | 114       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 307 | Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 1130.  | 6.1  | 114       |
| 308 | Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. American Heart Journal, 2000, 139, 609-617.   | 2.7  | 113       |
| 309 | Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure (ATMOSPHERE) study. European Journal of Heart Failure, 2011, 13, 107-114. | 7.1  | 113       |
| 310 | Influenza Vaccination in Patients With Chronic Heart Failure. JACC: Heart Failure, 2016, 4, 152-158.   | 4.1  | 112       |
| 311 | Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. New England Journal of Medicine, 2021, 385, 2325-2335.  | 27.0 | 112       |
| 312 | Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. European Journal of Heart Failure, 2005, 7, 710-721.   | 7.1  | 111       |
| 313 | Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. European Journal of Heart Failure, 2006, 8, 591-598.  | 7.1  | 111       |
| 314 | Indications and practical approach to non-invasive ventilation in acute heart failure. European Heart Journal, 2018, 39, 17-25.  | 2.2  | 111       |
| 315 | Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. European Journal of Heart Failure, 2012, 14, 268-277.  | 7.1  | 110       |
| 316 | High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation. Circulation, 2014, 129, 625-634.   | 1.6  | 110       |
| 317 | Terminology and definition of changes renal function in heart failure. European Heart Journal, 2014, 35, 3413-3416.  | 2.2  | 108       |
| 318 | Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. New England Journal of Medicine, 2021, 385, 2313-2324.  | 27.0 | 108       |
| 319 | Endothelium-Derived Hyperpolarizing Factor. Circulation, 2001, 103, 1702-1708.   | 1.6  | 107       |
| 320 | Adherence to medication according to sex and age in the CHARM programme. European Journal of Heart Failure, 2009, 11, 1092-1098.   | 7.1  | 107       |
| 321 | Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. European Journal of Heart Failure, 2009, 11, 795-801.   | 7.1  | 107       |
| 322 | Temporal Trends and Patterns in Mortality After Incident Heart Failure. JAMA Cardiology, 2019, 4, 1102.  | 6.1  | 107       |
| 323 | The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 2020, 35, 1700-1711.   | 0.7  | 107       |
| 324 | Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure. Journal of the American College of Cardiology, 2010, 56, 1196-1204.  | 2.8  | 105       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 325 | Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. European Heart Journal, 2015, 36, 1958-1966. | 2.2  | 105       |
| 326 | Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. European Journal of Heart Failure, 2015, 17, 242-247.   | 7.1  | 105       |
| 327 | Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. Circulation: Heart Failure, 2013, 6, 727-732.   | 3.9  | 103       |
| 328 | Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) – Added trial. American Heart Journal, 2006, 151, 985-991.  | 2.7  | 102       |
| 329 | Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. European Heart Journal, 2008, 29, 748-756.  | 2.2  | 102       |
| 330 | Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure, 2009, 11, 292-298.   | 7.1  | 102       |
| 331 | Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency. Journal of the American College of Cardiology, 2014, 63, 853-871.  | 2.8  | 102       |
| 332 | Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction. Circulation, 2005, 112, 3391-3399.   | 1.6  | 101       |
| 333 | Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. European Journal of Heart Failure, 2012, 14, 1257-1264.   | 7.1  | 101       |
| 334 | Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. Journal of the American College of Cardiology, 2016, 68, 241-248.   | 2.8  | 101       |
| 335 | Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.   | 2.2  | 101       |
| 336 | Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation, 2021, 143, 2129-2142.   | 1.6  | 101       |
| 337 | Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 329-340.  | 4.1  | 100       |
| 338 | Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study. Lancet, The, 2001, 358, 1213-1217.   | 13.7 | 99        |
| 339 | The clinical relevance of adrenomedullin: a promising profile?. , 2004, 103, 179-201.   |      | 99        |
| 340 | <scp>EURObservational</scp> Research Programme: a worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on <scp>PPCM</scp>. European Journal of Heart Failure, 2014, 16, 583-591.                                       | 7.1  | 99        |
| 341 | Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations. JACC: Heart Failure, 2014, 2, 289-297.   | 4.1  | 99        |
| 342 | A Review of Quality-of-Life Evaluations in Patients with Congestive Heart Failure. Pharmacoeconomics, 1999, 16, 247-271.  | 3.3  | 97        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 343 | The past, present and future of renin-angiotensin aldosterone system inhibition. International Journal of Cardiology, 2013, 167, 1677-1687.  | 1.7  | 97        |
| 344 | Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 601-612.  | 2.8  | 97        |
| 345 | Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Medicine, 2018, 15, e1002541.  | 8.4  | 97        |
| 346 | Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. European Heart Journal, 1999, 20, 1182-1190. | 2.2  | 96        |
| 347 | Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006541.   | 3.9  | 96        |
| 348 | Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal, 2009, 30, 2226-2232.   | 2.2  | 95        |
| 349 | Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 129-137.   | 7.1  | 95        |
| 350 | Is the Pregnancy Hormone Relaxin Also a Vasodilator Peptide Secreted by the Heart?. Circulation, 2002, 106, 292-295.   | 1.6  | 94        |
| 351 | The complex nature of informal care in home-based heart failure management. Journal of Advanced Nursing, 2008, 61, 373-383.  | 3.3  | 94        |
| 352 | Outcomes and Effect of Treatment According to Etiology in HFrEF. JACC: Heart Failure, 2019, 7, 457-465.  | 4.1  | 94        |
| 353 | Impaired endothelium-dependent vasodilatation in uraemia. Nephrology Dialysis Transplantation, 2000, 15, 1194-1200.  | 0.7  | 93        |
| 354 | Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. European Heart Journal, 2012, 33, 314-324.   | 2.2  | 93        |
| 355 | Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .   | 3.9  | 93        |
| 356 | Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure, 2018, 20, 888-895.   | 7.1  | 93        |
| 357 | Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. New England Journal of Medicine, 2015, 373, 2289-2290.  | 27.0 | 92        |
| 358 | Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. Circulation, 2015, 131, 1486-1494.   | 1.6  | 92        |
| 359 | Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 561-568.   | 3.9  | 91        |
| 360 | Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction. Circulation: Heart Failure, 2013, 6, 492-498.   | 3.9  | 91        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 361 | Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 317-326.  | 4.1  | 91        |
| 362 | Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 844-851.   | 7.1  | 91        |
| 363 | Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of <scp>DAPA-HF</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 2147-2156.         | 7.1  | 91        |
| 364 | Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. <i>European Heart Journal</i> , 2008, 29, 1739-1752.   | 2.2  | 90        |
| 365 | Heart Failure After Acute Myocardial Infarction. <i>Circulation</i> , 2008, 118, 2019-2021.  | 1.6  | 90        |
| 366 | Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms. <i>Circulation</i> , 2012, 126, 2317-2323.   | 1.6  | 90        |
| 367 | Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.                         | 2.2  | 90        |
| 368 | Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa. <i>Circulation</i> , 2011, 124, 2903-2908.   | 1.6  | 89        |
| 369 | Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .   | 3.9  | 89        |
| 370 | Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. <i>Lancet</i> , The, 1998, 352, 201-202.  | 13.7 | 88        |
| 371 | Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. <i>European Heart Journal</i> , 2007, 28, 326-333. | 2.2  | 88        |
| 372 | Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.  | 2.7  | 88        |
| 373 | Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016, 18, 328-336.  | 7.1  | 88        |
| 374 | Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFrEF. <i>Journal of the American College of Cardiology</i> , 2020, 75, 245-254.                                     | 2.8  | 88        |
| 375 | Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 882-894.   | 7.1  | 88        |
| 376 | Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2352-2361.  | 6.1  | 88        |
| 377 | Effects of Urotensin II in Human Arteries and Veins of Varying Caliber. <i>Circulation</i> , 2001, 103, 1378-1381.   | 1.6  | 87        |
| 378 | Ultrasound imaging of congestion in heart failure: examinations beyond the heart. <i>European Journal of Heart Failure</i> , 2021, 23, 703-712.  | 7.1  | 87        |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 379 | Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.  | 4.1  | 87        |
| 380 | Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes and Endocrinology, 2021, 9, 743-754.                   | 11.4 | 87        |
| 381 | Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes and Endocrinology, 2021, 9, 755-766.                                | 11.4 | 86        |
| 382 | Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. European Heart Journal, 1998, 19, 1829-1835.  | 2.2  | 85        |
| 383 | New Therapeutic Options in Congestive Heart Failure. Circulation, 2002, 105, 2223-2228.   | 1.6  | 85        |
| 384 | The prevalence and importance of frailty in heart failure with reduced ejection fraction - An analysis of <scp>PARADIGM-HF</scp> and <scp>ATMOSPHERE</scp>. European Journal of Heart Failure, 2020, 22, 2123-2133.   | 7.1  | 85        |
| 385 | Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation, 2021, 143, 438-448.   | 1.6  | 85        |
| 386 | Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal, 2008, 156, 623-632. | 2.7  | 84        |
| 387 | Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. European Journal of Heart Failure, 2009, 11, 684-690.  | 7.1  | 84        |
| 388 | Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. European Journal of Heart Failure, 2010, 12, 17-24.   | 7.1  | 84        |
| 389 | Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?. European Heart Journal, 2012, 33, 2764-2765.   | 2.2  | 84        |
| 390 | Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1845-1854.  | 2.8  | 84        |
| 391 | Efficacy of Sacubitril/Valsartan Relative to A Prior Decompensation. JACC: Heart Failure, 2016, 4, 816-822.   | 4.1  | 84        |
| 392 | Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. JAMA Cardiology, 2018, 3, 498.  | 6.1  | 84        |
| 393 | Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Therapy. Circulation: Heart Failure, 2016, 9, .   | 3.9  | 83        |
| 394 | Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 1199-1208.   | 4.4  | 83        |
| 395 | BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1149-1151.  | 3.6  | 83        |
| 396 | Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart, 2010, 96, 533-538.  | 2.9  | 82        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 397 | Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). American Journal of Nephrology, 2013, 37, 212-222.   | 3.1  | 82        |
| 398 | Selecting Patients for Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2009, 53, 1944-1959.  | 2.8  | 81        |
| 399 | Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open, 2014, 4, e005354-e005354.   | 1.9  | 81        |
| 400 | Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245.   | 1.6  | 81        |
| 401 | Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. European Journal of Heart Failure, 2011, 13, 148-153.   | 7.1  | 80        |
| 402 | The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). American Heart Journal, 2012, 164, 878-883.   | 2.7  | 80        |
| 403 | Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. Circulation: Heart Failure, 2014, 7, 953-959.  | 3.9  | 80        |
| 404 | Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (â€œPreserve). European Journal of Heart Failure, 2014, 16, 778-787.   | 7.1  | 80        |
| 405 | A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 2015, 36, 434-439.   | 2.2  | 80        |
| 406 | Palliative care for heart failure. BMJ: British Medical Journal, 2002, 325, 915-916.   | 2.3  | 79        |
| 407 | Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. Journal of Cardiac Failure, 2008, 14, 467-474.  | 1.7  | 79        |
| 408 | 'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq0 0 0 rgBT /Overlock 10 T | 2.2  | 79        |
| 409 | Prevention & Rehabilitation (EACPR). [Eur Heart J 2012;33:1635-1701, doi: 10.1093/eurheartj/ehs092]. European Heart Journal, 2012, 33, 2126-2126.  | 2.2  | 79        |
| 409 | The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. European Heart Journal, 2013, 34, 2823-2829.   | 2.2  | 79        |
| 410 | Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. PLoS Medicine, 2012, 9, e1001310.  | 8.4  | 78        |
| 411 | Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal, 2014, 35, 3442-3451.   | 2.2  | 78        |
| 412 | Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006539.  | 3.9  | 78        |
| 413 | Real-world studies no substitute for RCTs in establishing efficacy. Lancet, The, 2019, 393, 210-211.   | 13.7 | 78        |
| 414 | Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 862-874.   | 4.1  | 77        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 415 | Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. Journal of the American College of Cardiology, 2020, 76, 503-514.   | 2.8 | 77        |
| 416 | VALSartan In Acute myocardial infarction (VALIANT) trial: baseline characteristics in context. European Journal of Heart Failure, 2003, 5, 537-544.   | 7.1 | 76        |
| 417 | EMPA-REG – the “osmotic diuretic hypothesis”. Journal of Diabetes and Its Complications, 2016, 30, 3-4.   | 2.3 | 76        |
| 418 | Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 2013, 15, 947-959. | 7.1 | 75        |
| 419 | Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. European Journal of Heart Failure, 2013, 15, 551-559.   | 7.1 | 75        |
| 420 | International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation, 2015, 131, 43-53.   | 1.6 | 75        |
| 421 | Role of B-type Natriuretic Peptide and N-terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2017, 6, .   | 3.7 | 75        |
| 422 | Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. European Journal of Heart Failure, 2017, 19, 1186-1197.  | 7.1 | 75        |
| 423 | Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European Heart Journal, 2021, 42, 1216-1227.   | 2.2 | 75        |
| 424 | Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. JACC: Heart Failure, 2021, 9, 254-264.   | 4.1 | 75        |
| 425 | Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 184-197.   | 4.1 | 75        |
| 426 | Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. European Journal of Heart Failure, 2007, 9, 110-112.   | 7.1 | 74        |
| 427 | Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489.   | 7.1 | 74        |
| 428 | Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2019, 140, 1369-1379.  | 1.6 | 74        |
| 429 | Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal, 2021, 42, 3741-3752.  | 2.2 | 74        |
| 430 | Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2006, 152, 86-92.  | 2.7 | 74        |
| 431 | An economic analysis of specialist heart failure nurse management in the U.K. Can we afford not to implement it?. European Heart Journal, 2002, 23, 1369-1378.  | 2.2 | 73        |
| 432 | Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction?. Circulation, 2004, 110, 3281-3288.  | 1.6 | 73        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 433 | Plasma apelin concentration is depressed following acute myocardial infarction in man. <i>European Journal of Heart Failure</i> , 2009, 11, 551-558.   | 7.1  | 73        |
| 434 | “Hearts and minds”: association, causation and implication of cognitive impairment in heart failure. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 22.  | 6.2  | 73        |
| 435 | Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.  | 2.8  | 73        |
| 436 | The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1238-1245.  | 2.8  | 72        |
| 437 | Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). <i>American Heart Journal</i> , 2011, 162, 748-755.e3. | 2.7  | 72        |
| 438 | Role of diuretics, A blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. <i>BMJ, The</i> , 2013, 347, f6745-f6745.  | 6.0  | 72        |
| 439 | Statistical Controversies in Reporting of Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2648-2662.   | 2.8  | 72        |
| 440 | The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 429-441.   | 4.1  | 72        |
| 441 | Neurohumoral Pathways in Heart Failure With Preserved Systolic Function. <i>Progress in Cardiovascular Diseases</i> , 2005, 47, 357-366.   | 3.1  | 71        |
| 442 | Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. <i>European Heart Journal</i> , 2005, 26, 1759-1764.   | 2.2  | 71        |
| 443 | Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 607-616.  | 7.1  | 71        |
| 444 | Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012, 14, 681-695.   | 7.1  | 71        |
| 445 | Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). <i>European Heart Journal</i> , 2014, 35, 2714-2721.  | 2.2  | 71        |
| 446 | Treatment of Heart Failure with Spironolactone “ Trial and Tribulations. <i>New England Journal of Medicine</i> , 2004, 351, 526-528.  | 27.0 | 70        |
| 447 | Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 697-703.   | 11.4 | 70        |
| 448 | Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048.   | 7.1  | 70        |
| 449 | Relation between socioeconomic deprivation and death from a first myocardial infarction in Scotland: population based analysis. <i>BMJ: British Medical Journal</i> , 2001, 322, 1152-1153.  | 2.3  | 69        |
| 450 | Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. <i>Journal of Cardiac Failure</i> , 2004, 10, 155-164.   | 1.7  | 69        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 451 | Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. Hypertension, 2008, 51, 48-54.  | 2.7 | 69        |
| 452 | Sex Differences in Incidence, Mortality, and Survival in Individuals With Stroke in Scotland, 1986 to 2005. Stroke, 2009, 40, 1038-1043.  | 2.0 | 69        |
| 453 | Microvascular Obstruction Remains a Portent of Adverse Remodeling in Optimally Treated Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. Circulation: Cardiovascular Imaging, 2010, 3, 360-367.  | 2.6 | 69        |
| 454 | Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. Journal of the American Heart Association, 2019, 8, e013114.  | 3.7 | 69        |
| 455 | Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. JAMA Cardiology, 2018, 3, 164.  | 6.1 | 68        |
| 456 | Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). American Heart Journal, 2005, 150, 46-53.  | 2.7 | 67        |
| 457 | Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. European Journal of Heart Failure, 2007, 9, 865-871.  | 7.1 | 67        |
| 458 | CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. European Journal of Heart Failure, 2011, 13, 929-936.  | 7.1 | 67        |
| 459 | Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <i>LCZ696</i> , in patients with heart failure with preserved ejection fraction: an analysis of the <i>PARAMOUNT</i> trial. European Journal of Heart Failure, 2014, 16, 671-677. | 7.1 | 67        |
| 460 | Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. Journal of the American College of Cardiology, 2014, 64, 1106-1113.   | 2.8 | 67        |
| 461 | World Heart Federation Roadmap for Heart Failure. Global Heart, 2019, 14, 197.  | 2.3 | 67        |
| 462 | Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2005, 294, 1794.   | 7.4 | 66        |
| 463 | The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry. American Heart Journal, 2006, 151, 206-212.  | 2.7 | 66        |
| 464 | Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. European Journal of Heart Failure, 2007, 9, 1120-1127.  | 7.1 | 66        |
| 465 | Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 2010, 12, 617-622.  | 7.1 | 66        |
| 466 | Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. European Heart Journal, 2012, 33, 1137-1141.  | 2.2 | 66        |
| 467 | Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. Circulation, 2018, 138, 570-577.   | 1.6 | 66        |
| 468 | Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. Journal of Cardiac Failure, 2015, 21, 179-188.  | 1.7 | 65        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 469 | Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. <i>European Journal of Heart Failure</i> , 2018, 20, 295-303.  | 7.1 | 65        |
| 470 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.  | 2.2 | 65        |
| 471 | A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1175-1182.  | 7.1 | 64        |
| 472 | Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. <i>Clinical Research in Cardiology</i> , 2019, 108, 477-486.       | 3.3 | 64        |
| 473 | Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2020, 8, 800-810.   | 4.1 | 64        |
| 474 | Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 217-225. | 3.9 | 63        |
| 475 | Inflammatory cytokines in chronic heart failure: interleukin-6 is associated with adverse outcome. Results from CORONA. <i>European Journal of Heart Failure</i> , 2014, 16, 68-75.  | 7.1 | 63        |
| 476 | Income Inequality and Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 336-346.  | 4.1 | 63        |
| 477 | Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. <i>Circulation</i> , 2020, 142, 1205-1218.  | 1.6 | 63        |
| 478 | Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015, 36, 669-675.  | 2.2 | 62        |
| 479 | Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2018, 20, 760-768.   | 7.1 | 62        |
| 480 | Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.  | 1.6 | 62        |
| 481 | Effect of Angiotensin-(1-7) and Bradykinin in Patients With Heart Failure Treated With an ACE Inhibitor. <i>Hypertension</i> , 1999, 34, 457-460.  | 2.7 | 61        |
| 482 | Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Diabetes Care</i> , 2009, 32, 915-920.   | 8.6 | 61        |
| 483 | Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 42-47.   | 2.2 | 61        |
| 484 | Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. <i>Heart</i> , 2018, 104, 144-150.  | 2.9 | 61        |
| 485 | Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2009, 54, 59-69.  | 1.9 | 60        |
| 486 | Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1369-1376.   | 4.4 | 60        |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 487 | Which patients with heart failure should receive specialist palliative care?. European Journal of Heart Failure, 2018, 20, 1338-1347.   | 7.1  | 60        |
| 488 | Diabetic cardiomyopathy. Heart, 2019, 105, 337-345.   | 2.9  | 60        |
| 489 | Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure, 2010, 12, 557-565.  | 7.1  | 59        |
| 490 | Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 2012, 14, 909-915.                                | 7.1  | 59        |
| 491 | The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. Journal of Internal Medicine, 2012, 271, 436-443.   | 6.0  | 59        |
| 492 | Prognostic Effect of High-Sensitive Troponin T Assessment in Elderly Patients With Chronic Heart Failure. Circulation: Heart Failure, 2014, 7, 96-103.  | 3.9  | 59        |
| 493 | Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 86-94.   | 3.0  | 59        |
| 494 | Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. European Journal of Heart Failure, 2018, 20, 491-500. | 7.1  | 59        |
| 495 | Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiology, 2020, 5, 432.   | 6.1  | 59        |
| 496 | Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. European Journal of Heart Failure, 2020, 22, 898-901.  | 7.1  | 59        |
| 497 | Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. JAMA Cardiology, 2022, 7, 26.   | 6.1  | 59        |
| 498 | "I don't like Mondays"—day of the week of coronary heart disease deaths in Scotland: study of routinely collected data. BMJ: British Medical Journal, 2000, 320, 218-219.   | 2.3  | 58        |
| 499 | Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. European Journal of Heart Failure, 2001, 3, 495-502.  | 7.1  | 58        |
| 500 | Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. JACC: Heart Failure, 2016, 4, 870-880.   | 4.1  | 58        |
| 501 | Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). European Heart Journal, 2017, 38, ehw387.  | 2.2  | 58        |
| 502 | Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Tj ETQq0 0 0 rgBT /Overlock 10 T  | 3.9  | 58        |
| 503 | Changes in notions about heart failure. Lancet, The, 2001, 358, 432-434.  | 13.7 | 57        |
| 504 | Discordant Short- and Long-Term Outcomes Associated With Diabetes in Patients With Heart Failure: Importance of Age and Sex. Circulation: Heart Failure, 2008, 1, 234-241.  | 3.9  | 57        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 505 | High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2014, 20, 319-326.  | 1.7 | 57        |
| 506 | Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. American Heart Journal, 2015, 170, 290-297.e1.                                    | 2.7 | 57        |
| 507 | Making Sense of Statistics in Clinical Trials. Reports. Journal of the American College of Cardiology, 2015, 66, 2536-2549.  | 2.8 | 57        |
| 508 | Effect of dapagliflozin on anaemia in <sc>DAPA-HF</sc>. European Journal of Heart Failure, 2021, 23, 617-628.  | 7.1 | 57        |
| 509 | Neurohormonal Activation in Acute Heart Failure: Results from VERITAS. Cardiology, 2011, 119, 96-105.  | 1.4 | 56        |
| 510 | Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 387-393.  | 1.7 | 56        |
| 511 | Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. European Journal of Heart Failure, 2016, 18, 1238-1243.  | 7.1 | 56        |
| 512 | European Society of Cardiology - Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 311-320.                | 1.0 | 56        |
| 513 | Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure, 2018, 20, 1701-1709. | 7.1 | 56        |
| 514 | Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. JACC: Heart Failure, 2020, 8, 844-855.  | 4.1 | 56        |
| 515 | Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, 820-830.  | 3.9 | 56        |
| 516 | How should we optimize cardiac resynchronization therapy?. European Heart Journal, 2008, 29, 2458-2472.  | 2.2 | 55        |
| 517 | Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovascular Drugs and Therapy, 2017, 31, 545-549.   | 2.6 | 55        |
| 518 | Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. Circulation: Heart Failure, 2018, 11, e004745.  | 3.9 | 55        |
| 519 | Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1118-1127.  | 6.1 | 55        |
| 520 | The struggle towards a Universal Definition of Heart Failure - how to proceed?. European Heart Journal, 2021, 42, 2331-2343.   | 2.2 | 55        |
| 521 | The prevalence, nature, and importance of hematologic abnormalities in heart failure. American Heart Journal, 2006, 151, 1313-1321.  | 2.7 | 54        |
| 522 | Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?. American Heart Journal, 2009, 157, 1088-1096.  | 2.7 | 54        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 523 | Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure. American Journal of Medicine, 2013, 126, 701-708.   | 1.5 | 54        |
| 524 | The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 2016, 18, 1491-1498.   | 7.1 | 54        |
| 525 | Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the <sc>CHARM</sc>â€study programme. European Journal of Heart Failure, 2016, 18, 1508-1517. | 7.1 | 54        |
| 526 | The prognostic value of troponin T and Nâ€terminal pro Bâ€type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 2019, 21, 40-49.   | 7.1 | 54        |
| 527 | EndothelinReceptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. Journal of the American College of Cardiology, 1999, 33, 932-938.   | 2.8 | 53        |
| 528 | Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial. Journal of Cardiac Failure, 2010, 16, 128-134.  | 1.7 | 53        |
| 529 | Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 845-855.  | 4.5 | 53        |
| 530 | Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 2015, 36, 1106-1114.  | 2.2 | 53        |
| 531 | Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .   | 3.9 | 53        |
| 532 | Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .   | 3.9 | 53        |
| 533 | Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. Current Atherosclerosis Reports, 2019, 21, 41.   | 4.8 | 53        |
| 534 | Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in HeartâFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 372-381.   | 4.1 | 53        |
| 535 | Readmission and death in patients admitted with newâ€onset versus worsening of chronic heart failure: insights from a nationwide cohort. European Journal of Heart Failure, 2020, 22, 1777-1785.   | 7.1 | 53        |
| 536 | A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International, 2022, 101, 174-184.                          | 5.2 | 53        |
| 537 | Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.  | 1.6 | 53        |
| 538 | Changes in Nâ€terminal proâ€Bâ€type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the lâ€Preserve study. European Journal of Heart Failure, 2015, 17, 809-817.   | 7.1 | 52        |
| 539 | Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circulation: Heart Failure, 2016, 9, .  | 3.9 | 52        |
| 540 | Contribution of cardiac and extraâ€cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure, 2018, 20, 504-510.   | 7.1 | 52        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 541 | Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018, 138, 2763-2773.   | 1.6  | 52        |
| 542 | Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019, 42, 1792-1799.   | 8.6  | 52        |
| 543 | Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.   | 7.1  | 52        |
| 544 | Higher Body Mass Index in Adolescence Predicts Cardiomyopathy Risk in Midlife. <i>Circulation</i> , 2019, 140, 117-125.   | 1.6  | 52        |
| 545 | The Pharmacoeconomics of ACE Inhibitors in Chronic Heart Failure. <i>Pharmacoeconomics</i> , 1996, 9, 188-197.  | 3.3  | 51        |
| 546 | Mapping the emergence of heart disease in a black, urban population in Africa: The Heart of Soweto Study. <i>International Journal of Cardiology</i> , 2006, 108, 101-108.  | 1.7  | 51        |
| 547 | A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. <i>American Heart Journal</i> , 2011, 161, 210-219.e1.              | 2.7  | 51        |
| 548 | Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitusâ€”Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018, 203, 30-38. | 2.7  | 51        |
| 549 | The Serendipitous Story of SGLT2 Inhibitors in Heart Failure. <i>Circulation</i> , 2019, 139, 2537-2541.  | 1.6  | 51        |
| 550 | Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.  | 1.6  | 51        |
| 551 | Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1818-1824.   | 30.7 | 51        |
| 552 | Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. <i>European Journal of Heart Failure</i> , 2007, 9, 429-434.   | 7.1  | 50        |
| 553 | Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. <i>European Heart Journal</i> , 2007, 28, 685-691.   | 2.2  | 50        |
| 554 | Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. <i>American Heart Journal</i> , 2014, 168, 23-29.e2.  | 2.7  | 50        |
| 555 | Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (<scp>VALIANT</scp>). <i>European Journal of Heart Failure</i> , 2015, 17, 301-312.  | 7.1  | 50        |
| 556 | Return to the Workforce After First Hospitalization for Heart Failure. <i>Circulation</i> , 2016, 134, 999-1009.  | 1.6  | 50        |
| 557 | Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. <i>Heart</i> , 2018, 104, 1006-1013.   | 2.9  | 50        |
| 558 | Randomized Trials Versus CommonÂSense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.   | 2.8  | 50        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 559 | Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021, 44, 586-594.  | 8.6  | 50        |
| 560 | Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. <i>Heart Rhythm</i> , 2006, 3, 313-316.  | 0.7  | 49        |
| 561 | Is a reduction in albuminuria associated with renal and cardiovascular protection? A <i>post hoc</i> analysis of the <scp>ALTITUDE</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 169-177.  | 4.4  | 49        |
| 562 | How robust are clinical trials in heart failure?. <i>European Heart Journal</i> , 2017, 38, ehw427.   | 2.2  | 49        |
| 563 | Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 807-820.  | 4.1  | 49        |
| 564 | Red cell distribution width has incremental prognostic value to B-type natriuretic peptide in acute heart failure. <i>European Journal of Heart Failure</i> , 2009, 11, 1152-1154.  | 7.1  | 48        |
| 565 | Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. <i>American Heart Journal</i> , 2009, 157, 957-970.  | 2.7  | 48        |
| 566 | How Small Is Too Small? A Systematic Review of Center Volume and Outcome After Cardiac Transplantation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 783-790.   | 2.2  | 48        |
| 567 | Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. <i>European Journal of Heart Failure</i> , 2015, 17, 906-916.  | 7.1  | 48        |
| 568 | Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <scp>MAGGIC</scp> meta-analysis. <i>European Journal of Heart Failure</i> , 2015, 17, 1182-1191.   | 7.1  | 48        |
| 569 | Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart OMics™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , 2016, 14, 181. | 5.5  | 48        |
| 570 | Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1647-1656.   | 0.7  | 48        |
| 571 | Effects of a Xanthine Oxidase/Hypoxanthine Free Radical and Reactive Oxygen Species Generating System on Endothelial Function in New Zealand White Rabbit Aortic Rings. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, 792-797.  | 1.9  | 47        |
| 572 | Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. <i>Current Heart Failure Reports</i> , 2006, 3, 175-180.  | 3.3  | 47        |
| 573 | Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme. <i>European Journal of Heart Failure</i> , 2007, 9, 510-517.   | 7.1  | 47        |
| 574 | Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. <i>European Heart Journal</i> , 2008, 29, 3069-3069.  | 2.2  | 47        |
| 575 | Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). <i>European Heart Journal</i> , 2009, 30, 1450-1456.  | 2.2  | 47        |
| 576 | Lessons from the TOPCAT Trial. <i>New England Journal of Medicine</i> , 2014, 370, 1453-1454.   | 27.0 | 47        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 577 | Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges. <i>European Journal of Heart Failure</i> , 2016, 18, 977-986.  | 7.1  | 47        |
| 578 | Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , 2016, 18, 290-297.   | 7.1  | 47        |
| 579 | Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2101.  | 7.4  | 47        |
| 580 | Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.       | 7.1  | 47        |
| 581 | Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021, 44, 1894-1897.   | 8.6  | 47        |
| 582 | Role of Bradykinin in the Vasodilator Effects of Losartan and Enalapril in Patients With Heart Failure. <i>Circulation</i> , 1999, 100, 268-273.   | 1.6  | 46        |
| 583 | Treatment of chronic heart failure: a comparison between the major guidelines. <i>European Heart Journal</i> , 2006, 27, 1773-1777.  | 2.2  | 46        |
| 584 | Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1644-1656.   | 2.8  | 46        |
| 585 | The interrelationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. <i>European Journal of Heart Failure</i> , 2010, 12, 1229-1237.   | 7.1  | 45        |
| 586 | Liver function tests in patients with acute heart failure and associated outcomes: insights from <scp>ASCENDâ€HF</scp>. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.  | 7.1  | 45        |
| 587 | Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 68-77.  | 4.1  | 45        |
| 588 | Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1139-1145.  | 7.1  | 45        |
| 589 | Electrical cardioversion for atrial fibrillation: outcomes in "real-life" clinical practice. <i>International Journal of Cardiology</i> , 2001, 81, 29-35.   | 1.7  | 44        |
| 590 | Vasoconstrictor Effect of the Angiotensin-Converting Enzyme-Resistant, Chymase-Specific Substrate [Pro <sup>11</sup> <sub>D</sub> -Ala <sup>12</sup> <sub>Angiotensin I</sub> in Human Dorsal Hand Veins. <i>Circulation</i> , 2001, 104, 1805-1808. | 1.6  | 44        |
| 591 | Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. <i>European Heart Journal</i> , 2010, 31, 211-221.  | 2.2  | 44        |
| 592 | Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. <i>International Journal of Cardiology</i> , 2013, 168, 1094-1101.          | 1.7  | 44        |
| 593 | Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. <i>Lancet, The</i> , 2017, 389, 1831-1840.                                     | 13.7 | 44        |
| 594 | Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1717-1727.   | 2.8  | 44        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 595 | Effect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2004, 25, 1920-1926.  | 2.2  | 43        |
| 596 | Neprilysin Inhibition for Heart Failure. New England Journal of Medicine, 2014, 371, 2335-2337.  | 27.0 | 43        |
| 597 | Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. Circulation: Heart Failure, 2014, 7, 895-902.                                      | 3.9  | 43        |
| 598 | The Emerging Potential of the Apelin-APJ System in Heart Failure. Journal of Cardiac Failure, 2015, 21, 489-498.   | 1.7  | 43        |
| 599 | B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulmonary Medicine, 2017, 17, 11.   | 2.0  | 43        |
| 600 | Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. JACC: Heart Failure, 2018, 6, 564-569.   | 4.1  | 43        |
| 601 | Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. European Journal of Heart Failure, 2019, 21, 345-351.  | 7.1  | 43        |
| 602 | Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology, 2008, 52, 2000-2007. | 2.8  | 42        |
| 603 | Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart Failure. Circulation: Heart Failure, 2013, 6, 91-98.   | 3.9  | 42        |
| 604 | Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. Circulation: Heart Failure, 2014, 7, 918-925.  | 3.9  | 42        |
| 605 | Practical approach on frail older patients attended for acute heart failure. International Journal of Cardiology, 2016, 222, 62-71.  | 1.7  | 42        |
| 606 | Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. European Journal of Heart Failure, 2018, 20, 268-277.  | 7.1  | 42        |
| 607 | Association is not causation: treatment effects cannot be estimated from observational data in heart failure. European Heart Journal, 2018, 39, 3417-3438.   | 2.2  | 42        |
| 608 | Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. European Journal of Heart Failure, 1999, 1, 67-72.   | 7.1  | 41        |
| 609 | Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. Circulation, 2014, 130, 958-965.   | 1.6  | 41        |
| 610 | Improving outcomes in heart failure: a personal perspective. European Heart Journal, 2015, 36, 3467-3470.  | 2.2  | 41        |
| 611 | European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 81-86.  | 1.0  | 41        |
| 612 | The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. American Heart Journal, 2017, 187, 145-155.  | 2.7  | 41        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 613 | Accelerated and personalized therapy for heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 2573-2587.  | 2.2  | 41        |
| 614 | Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure–Assessment of Reduction in Mortality and morbidity programme. <i>European Heart Journal</i> , 2008, 29, 3022-3028.      | 2.2  | 40        |
| 615 | Fatigue as a Predictor of Outcome in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 187-197.   | 4.1  | 40        |
| 616 | Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. <i>European Heart Journal</i> , 2016, 37, 466-472.   | 2.2  | 40        |
| 617 | IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005133.   | 3.9  | 40        |
| 618 | Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 165-178.  | 3.0  | 40        |
| 619 | Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021, 144, 199-209.  | 1.6  | 40        |
| 620 | Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 24-34.  | 11.4 | 40        |
| 621 | Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022, 75, 523.e1-523.e114.   | 1.2  | 40        |
| 622 | Even low-dose aspirin inhibits arachidonic acid–induced vasodilation in heart failure. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 530-537.  | 4.7  | 39        |
| 623 | Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. <i>American Heart Journal</i> , 2011, 162, 685-691. | 2.7  | 39        |
| 624 | Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. <i>European Journal of Heart Failure</i> , 2011, 13, 1305-1313.   | 7.1  | 39        |
| 625 | Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. <i>European Journal of Heart Failure</i> , 2015, 17, 434-441.   | 7.1  | 39        |
| 626 | Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 309-317.  | 11.4 | 39        |
| 627 | Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2893-2904.  | 2.8  | 39        |
| 628 | How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 506-522.                               | 2.4  | 39        |
| 629 | Endothelin receptor antagonism in patients with chronic heart failure. <i>Cardiovascular Research</i> , 2000, 47, 166-172.   | 3.8  | 38        |
| 630 | Failing ageing hearts. <i>European Heart Journal</i> , 2001, 22, 1978-1990.  | 2.2  | 38        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 631 | Trends in case-fatality in 22 968 patients admitted for the first time with atrial fibrillation in Scotland, 1986–1995. <i>International Journal of Cardiology</i> , 2002, 82, 229-236.  | 1.7  | 38        |
| 632 | How much responsibility should heart failure nurses take?. <i>European Journal of Heart Failure</i> , 2005, 7, 351-361.  | 7.1  | 38        |
| 633 | Determining the most appropriate components for a composite clinical trial outcome. <i>American Heart Journal</i> , 2008, 156, 633-640.  | 2.7  | 38        |
| 634 | Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. <i>American Heart Journal</i> , 2011, 161, 224-232.  | 2.7  | 38        |
| 635 | Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. <i>European Journal of Heart Failure</i> , 2012, 14, 185-192.         | 7.1  | 38        |
| 636 | Effects of Neutral Endopeptidase (Neprilysin) Inhibition on the Response to Other Vasoactive Peptides in Small Human Resistance Arteries: Studies with Thiorphan and Omapatrilat. <i>Cardiovascular Therapeutics</i> , 2014, 32, 13-18.  | 2.5  | 38        |
| 637 | Thyroid-Stimulating Hormone and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2014, 2, 35-40.  | 4.1  | 38        |
| 638 | Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. <i>Diabetes Care</i> , 2018, 41, 1285-1291.   | 8.6  | 38        |
| 639 | Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 1226. | 6.1  | 38        |
| 640 | Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019, 21, 577-587.   | 7.1  | 38        |
| 641 | Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 188-198.   | 4.1  | 38        |
| 642 | A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2356-2362.   | 2.2  | 38        |
| 643 | Heart failure: we need more trials in typical patients. <i>European Heart Journal</i> , 2000, 21, 699-700.   | 2.2  | 37        |
| 644 | Effect of socioeconomic deprivation on the population risk of incident heart failure hospitalisation: An analysis of the Renfrew/Paisley Study. <i>European Journal of Heart Failure</i> , 2006, 8, 856-863.   | 7.1  | 37        |
| 645 | ACE Inhibitors in Cardiovascular Disease – Unbeatable?. <i>New England Journal of Medicine</i> , 2008, 358, 1615-1616.   | 27.0 | 37        |
| 646 | Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1301-1305.  | 1.9  | 37        |
| 647 | Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 554-561.  | 3.4  | 37        |
| 648 | Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.   | 3.2  | 37        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 649 | Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .  | 3.9  | 37        |
| 650 | Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.   | 7.1  | 37        |
| 651 | A1 H spin echo and 51V NMR study of the interaction of vanadate with intact erythrocytes. <i>Journal of Biological Inorganic Chemistry</i> , 1997, 2, 235-241.  | 2.6  | 36        |
| 652 | ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects. <i>American Heart Journal</i> , 2001, 141, 800-807.   | 2.7  | 36        |
| 653 | Impact of erythropoiesisâ€stimulating agents on morbidity and mortality in patients with heart failure: an updated, postâ€TREAT metaâ€analysis. <i>European Journal of Heart Failure</i> , 2010, 12, 936-942.   | 7.1  | 36        |
| 654 | Falling Cardiovascular Mortality in Heartâ€Failure With Reduced Ejection Fraction and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , 2015, 3, 603-614.  | 4.1  | 36        |
| 655 | Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 169-176.   | 7.1  | 36        |
| 656 | The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCENDâ€HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.  | 7.1  | 36        |
| 657 | The ICD in Heart Failure â€” Time for a Rethink?. <i>New England Journal of Medicine</i> , 2016, 375, 1283-1284.  | 27.0 | 36        |
| 658 | Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017, 38, ehw509.  | 2.2  | 36        |
| 659 | Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 834-844.  | 7.1  | 36        |
| 660 | Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021, 23, 1662-1672.   | 7.1  | 36        |
| 661 | The Kidney Protective Effects of the Sodiumâ€Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. <i>Kidney International Reports</i> , 2022, 7, 436-443.  | 0.8  | 36        |
| 662 | Reduced costs with bisoprolol treatment for heart failure; an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). <i>European Heart Journal</i> , 2001, 22, 1021-1031.   | 2.2  | 35        |
| 663 | Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2005, 27, 1447-1458.  | 2.2  | 35        |
| 664 | Assessment of Dyspnea in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1441-1448.   | 2.8  | 35        |
| 665 | Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>American Heart Journal</i> , 2013, 166, 935-940.e1. | 2.7  | 35        |
| 666 | Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy. <i>Circulation: Heart Failure</i> , 2013, 6, 711-718.  | 3.9  | 35        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 667 | History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 960-966.  | 3.9 | 35        |
| 668 | Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 1201-1207.   | 7.1 | 35        |
| 669 | Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.   | 4.1 | 35        |
| 670 | Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2016, 134, 1785-1787. | 1.6 | 35        |
| 671 | Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 20-28.  | 1.7 | 35        |
| 672 | Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 514-522.   | 7.1 | 35        |
| 673 | Conduct of Clinical Trials in the Era of COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2368-2378.   | 2.8 | 35        |
| 674 | Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1961-1973.  | 2.8 | 35        |
| 675 | Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.   | 1.6 | 35        |
| 676 | Free radical scavenging: a potentially beneficial action of thiol-containing angiotensin converting enzyme inhibitors. <i>Biochemical Society Transactions</i> , 1990, 18, 1184-1185.  | 3.4 | 34        |
| 677 | Seasonal variation in morbidity and mortality related to atrial fibrillation. <i>International Journal of Cardiology</i> , 2004, 97, 283-288.  | 1.7 | 34        |
| 678 | Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction†. <i>European Journal of Heart Failure</i> , 2006, 8, 577-584.   | 7.1 | 34        |
| 679 | Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 792-799.   | 7.1 | 34        |
| 680 | NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e017462.   | 3.7 | 34        |
| 681 | Serum potassium in the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2056-2064.  | 7.1 | 34        |
| 682 | Use of the Win Ratio in Cardiovascular Trials. <i>JACC: Heart Failure</i> , 2020, 8, 441-450.  | 4.1 | 34        |
| 683 | Signalling mechanisms underlying the myogenic response in human subcutaneous resistance arteries. <i>Cardiovascular Research</i> , 2001, 49, 828-837.  | 3.8 | 33        |
| 684 | Patients strategies for managing medication for chronic heart failure. <i>International Journal of Cardiology</i> , 2006, 109, 66-73.  | 1.7 | 33        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 685 | Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. <i>American Heart Journal</i> , 2008, 155, 87-93.                                      | 2.7 | 33        |
| 686 | A randomised trial of a pre-synaptic stimulator of DA <sub>2</sub> -dopaminergic and $\alpha_2$ -adrenergic receptors on morbidity and mortality in patients with heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 89-95.      | 7.1 | 33        |
| 687 | Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). <i>American Heart Journal</i> , 2010, 160, 145-151. | 2.7 | 33        |
| 688 | Comorbidities and Differential Diagnosis in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2014, 10, 481-501.   | 2.1 | 33        |
| 689 | Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure. <i>American Journal of Cardiology</i> , 2015, 116, 155-161.                             | 1.6 | 33        |
| 690 | MRAs in Elderly HF Patients. <i>JACC: Heart Failure</i> , 2019, 7, 1012-1021.   | 4.1 | 33        |
| 691 | Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: <sc>PARAGONâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 2093-2101.                          | 7.1 | 33        |
| 692 | Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1662-1671.  | 7.1 | 33        |
| 693 | Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <sc>DAPAâ€HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 601-613.                             | 7.1 | 33        |
| 694 | Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <sc>DAPAâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 513-525.   | 7.1 | 33        |
| 695 | Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. <i>American Heart Journal</i> , 1993, 126, 879-886.   | 2.7 | 32        |
| 696 | Effects of Chronic Norepinephrine Administration on Cardiac Function in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 584-589.  | 1.9 | 32        |
| 697 | Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1234-1238.   | 2.8 | 32        |
| 698 | Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. <i>American Heart Journal</i> , 2015, 170, 322-329.e4.   | 2.7 | 32        |
| 699 | The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017, 188, 35-41.  | 2.7 | 32        |
| 700 | Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000523.   | 2.8 | 32        |
| 701 | Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients. <i>PLoS Medicine</i> , 2019, 16, e1002805.   | 8.4 | 32        |
| 702 | Adrenomedullin selectively inhibits angiotensin II-induced aldosterone secretion in humans. <i>Journal of Hypertension</i> , 2000, 18, 61-64.   | 0.5 | 31        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 703 | Substantial between-hospital variation in outcome following first emergency admission for heart failure. <i>European Heart Journal</i> , 2002, 23, 650-657.   | 2.2 | 31        |
| 704 | Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. <i>Heart</i> , 2010, 96, 838-842.   | 2.9 | 31        |
| 705 | Mechanisms and Predictors of Mitral Regurgitation after High-Risk Myocardial Infarction. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 535-542.  | 2.8 | 31        |
| 706 | Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Española De Cardiología</i> , 2012, 65, 938.e1-938.e59.  | 1.2 | 31        |
| 707 | Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000011.   | 2.8 | 31        |
| 708 | The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from <scp>CIBIS</scp>, <scp>COPERNICUS</scp> and <scp>SENIORS</scp> compared with stratified subsets from <scp>MERIT</scp> and <scp>HF</scp>. <i>Journal of Internal Medicine</i> , 2014, 275, 134-143.  | 6.0 | 31        |
| 709 | Sacubitril/Valsartan (LCZ696) in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 133-165.  | 1.8 | 31        |
| 710 | Rationale for and design of the <scp>TRUE-AHF</scp> trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.   | 7.1 | 31        |
| 711 | Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2353-2355.   | 2.2 | 31        |
| 712 | The acute vascular effects of frusemide in heart failure. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 9-13.   | 2.4 | 30        |
| 713 | Anemia and heart failure. <i>Current Heart Failure Reports</i> , 2004, 1, 176-182.  | 3.3 | 30        |
| 714 | The treatment of heart failure with preserved ejection fraction (‘‘diastolic heart failure’’). <i>Heart Failure Reviews</i> , 2006, 11, 141-146.  | 3.9 | 30        |
| 715 | Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Added trial. <i>European Journal of Heart Failure</i> , 2008, 10, 157-163. | 7.1 | 30        |
| 716 | Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011, 13, 746-754.   | 7.1 | 30        |
| 717 | Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015, 36, 2310-2317.  | 2.2 | 30        |
| 718 | Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 256-264.   | 4.1 | 30        |
| 719 | Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <i>American Journal of Nephrology</i> , 2018, 48, 260-268.  | 3.1 | 30        |
| 720 | Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 497-509.   | 7.1 | 30        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 721 | Increasing the impact of cardiological treatments. How best to reduce deaths. European Heart Journal, 1999, 20, 1386-1392.   | 2.2 | 29        |
| 722 | High-risk myocardial infarction in the young: The VALSartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal, 2008, 155, 706-711.  | 2.7 | 29        |
| 723 | Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 2010, 8, 23.   | 5.5 | 29        |
| 724 | Cause of Death in Patients With Diabetic CKD Enrolled in theÂTrial to Reduce Cardiovascular Events With Aranesp TherapyÂ(TREAT). American Journal of Kidney Diseases, 2015, 66, 429-440.   | 1.9 | 29        |
| 725 | Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal, 2015, 36, 2463-2469.   | 2.2 | 29        |
| 726 | Efficacy and safety of sodiumâ€“glucose coâ€“transporter 2 inhibition according to left ventricular ejection fraction in DAPAâ€“HF. European Journal of Heart Failure, 2020, 22, 1247-1258.  | 7.1 | 29        |
| 727 | $\hat{I}^2_{<sub>1</sub>}$ -Adrenoreceptor Autoantibodies in Heart Failure. Circulation: Heart Failure, 2020, 13, e006155.   | 3.9 | 29        |
| 728 | Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. European Heart Journal, 2005, 26, 2114-2119.  | 2.2 | 28        |
| 729 | Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes. Diabetes Care, 2011, 34, 1394-1396.  | 8.6 | 28        |
| 730 | Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC metaâ€“analysis report. European Journal of Heart Failure, 2013, 15, 1220-1227.   | 7.1 | 28        |
| 731 | Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the <scp>VERITAS</scp> study. European Journal of Heart Failure, 2014, 16, 1362-1371.  | 7.1 | 28        |
| 732 | C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2016, 68, 873-881.  | 1.9 | 28        |
| 733 | Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 377-382.   | 0.5 | 28        |
| 734 | Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failureâ€“does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (<scp>VERITAS</scp>). European Journal of Heart Failure, 2017, 19, 739-747. | 7.1 | 28        |
| 735 | Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. Canadian Journal of Cardiology, 2017, 33, 1472-1477.  | 1.7 | 28        |
| 736 | Baseline characteristics and enrichment results from the <scp>SONAR</scp> trial. Diabetes, Obesity and Metabolism, 2018, 20, 1829-1835.  | 4.4 | 28        |
| 737 | Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 727-735.  | 2.8 | 28        |
| 738 | Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 528-538.  | 7.1 | 28        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 739 | Endpoints in Heart Failure Drug Development. JACC: Heart Failure, 2020, 8, 429-440.  | 4.1 | 28        |
| 740 | Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 2022, 145, 87-89.  | 1.6 | 28        |
| 741 | Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPA-HF</scp>. European Journal of Heart Failure, 2022, 24, 1066-1076.   | 7.1 | 28        |
| 742 | Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients. JAMA Internal Medicine, 2022, 182, 592.  | 5.1 | 28        |
| 743 | Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 2022, 65, 1085-1097.   | 6.3 | 28        |
| 744 | Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. American Journal of Medicine, 2000, 109, 489-492.  | 1.5 | 27        |
| 745 | Making sense of SENIORS. European Heart Journal, 2005, 26, 203-206.  | 2.2 | 27        |
| 746 | Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. Journal of Cardiac Failure, 2016, 22, 815-822.  | 1.7 | 27        |
| 747 | Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 2018, 20, 1601-1610. | 7.1 | 27        |
| 748 | Clinical Trials Update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovascular Drugs and Therapy, 2007, 21, 459-465.   | 2.6 | 26        |
| 749 | Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. European Heart Journal, 2008, 30, 338-345.   | 2.2 | 26        |
| 750 | Age- and Sex-Specific Trends in Fatal Incidence and Hospitalized Incidence of Stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 475-483.  | 2.2 | 26        |
| 751 | Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose Tolerance. Circulation: Heart Failure, 2013, 6, 203-210.  | 3.9 | 26        |
| 752 | Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart, 2014, 100, 1681-1687.   | 2.9 | 26        |
| 753 | Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. European Journal of Heart Failure, 2016, 18, 1162-1171.   | 7.1 | 26        |
| 754 | Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 18 26   |     |           |
| 755 | Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. Journal of Diabetes Research, 2018, 2018, 1-9.  | 2.3 | 26        |
| 756 | Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Circulation: Heart Failure, 2018, 11, e004926.  | 3.9 | 26        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 757 | Risk stratification scores for patients with acute heart failure in the Emergency Department: A systematic review. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 375-398.   | 1.0 | 26        |
| 758 | Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021, 77, 546-556.  | 2.7 | 26        |
| 759 | Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 678.   | 6.1 | 26        |
| 760 | Head-to-head comparison of contemporary heart failure risk scores. <i>European Journal of Heart Failure</i> , 2021, 23, 2035-2044.  | 7.1 | 26        |
| 761 | Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 377-386.   | 7.1 | 25        |
| 762 | Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002092.   | 3.7 | 25        |
| 763 | Global Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e007901.  | 3.9 | 25        |
| 764 | Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021, 44, 1877-1884.  | 8.6 | 25        |
| 765 | Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2005, 7, 650-656.                                      | 7.1 | 24        |
| 766 | Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>American Heart Journal</i> , 2006, 152, 183-189.  | 2.7 | 24        |
| 767 | Is Microvolt T-Wave Alternans the Answer to Risk Stratification in Heart Failure?. <i>Circulation</i> , 2007, 116, 2984-2991.   | 1.6 | 24        |
| 768 | Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). <i>European Journal of Heart Failure</i> , 2010, 12, 698-705.                                     | 7.1 | 24        |
| 769 | Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. <i>BMC Neurology</i> , 2011, 11, 38.  | 1.8 | 24        |
| 770 | Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.  | 7.1 | 24        |
| 771 | Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016, 5, . | 3.7 | 24        |
| 772 | Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. <i>Heart</i> , 2019, 105, 1325-1334.  | 2.9 | 24        |
| 773 | The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. <i>European Heart Journal</i> , 2021, 42, 1199-1202.  | 2.2 | 24        |
| 774 | Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 632-643.  | 7.1 | 24        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 775 | The assessment of the HO <sup>2</sup> scavenging action of therapeutic agents. Journal of Pharmaceutical and Biomedical Analysis, 1994, 12, 863-866.  | 2.8 | 23        |
| 776 | Attenuation of endothelin-1 induced vasoconstriction by 17 $\beta$ estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. Journal of the American College of Cardiology, 2001, 37, 1367-1373.   | 2.8 | 23        |
| 777 | Altered diaphragm position and function in patients with chronic heart failure. European Journal of Heart Failure, 2001, 3, 183-187.  | 7.1 | 23        |
| 778 | Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal, 2005, 150, 323-329.  | 2.7 | 23        |
| 779 | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2012, 2, e001925.   | 1.9 | 23        |
| 780 | When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches. Circulation: Heart Failure, 2012, 5, 294-302.   | 3.9 | 23        |
| 781 | Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct. American Heart Journal, 2013, 166, 208-216.e28.   | 2.7 | 23        |
| 782 | Large streamlined trials in cardiovascular disease. European Heart Journal, 2014, 35, 544-548.  | 2.2 | 23        |
| 783 | Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure, 2018, 20, 323-331. | 7.1 | 23        |
| 784 | Income level and inequality as complement to geographical differences in cardiovascular trials. American Heart Journal, 2019, 218, 66-74.   | 2.7 | 23        |
| 785 | Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2021, 9, 374-382.   | 4.1 | 23        |
| 786 | The effect of atrial natriuretic factor on urinary albumin and ??; 2-microglobulin excretion in man. Journal of Hypertension, 1988, 6, 783-786.   | 0.5 | 22        |
| 787 | An Economic Analysis of the Survival and Ventricular Enlargement (SAVE) Study. Pharmacoeconomics, 1997, 12, 182-192.  | 3.3 | 22        |
| 788 | Using Measures of Disease Progression to Determine Therapeutic Effect. Journal of the American College of Cardiology, 2006, 48, 434-437.  | 2.8 | 22        |
| 789 | Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. American Journal of Cardiology, 2008, 101, 925-929.  | 1.6 | 22        |
| 790 | The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sciences, 2012, 91, 743-748.  | 4.3 | 22        |
| 791 | Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <sc>ASCEND-HF</sc>. European Journal of Heart Failure, 2015, 17, 340-346.   | 7.1 | 22        |
| 792 | Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. Circulation: Heart Failure, 2015, 8, 717-724.  | 3.9 | 22        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 793 | Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. <i>International Journal of Cardiology</i> , 2016, 209, 310-316.                          | 1.7  | 22        |
| 794 | Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.   | 7.1  | 22        |
| 795 | From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). <i>Journal of the American College of Cardiology</i> , 2019, 74, 683-698.  | 2.8  | 22        |
| 796 | Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 231-241.  | 1.0  | 22        |
| 797 | Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. <i>JACC: Heart Failure</i> , 2021, 9, 13-24.  | 4.1  | 22        |
| 798 | What are the clinical consequences of anemia in patients with chronic heart failure?. <i>Journal of Cardiac Failure</i> , 2004, 10, S10-S12.  | 1.7  | 21        |
| 799 | Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. <i>Heart Rhythm</i> , 2007, 4, 308-313.   | 0.7  | 21        |
| 800 | Approaches to the treatment of anaemia in patients with chronic heart failure. <i>Heart Failure Reviews</i> , 2008, 13, 431-438.  | 3.9  | 21        |
| 801 | Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial) of Erythropoietin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 61, 238-246.  | 1.9  | 21        |
| 802 | Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2841-2850.                              | 0.7  | 21        |
| 803 | Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. <i>ESC Heart Failure</i> , 2015, 2, 25-36.  | 3.1  | 21        |
| 804 | Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 478-486.                      | 4.1  | 21        |
| 805 | Lessons in Uncertainty and Humility â€” Clinical Trials Involving Hypertension. <i>New England Journal of Medicine</i> , 2016, 375, 1756-1766.  | 27.0 | 21        |
| 806 | Referral for Specialist Follow-up and Its Association With Post-discharge Mortality Among Patients With Systolic Heart Failure (from the National Heart Failure Audit for England and Wales). <i>American Journal of Cardiology</i> , 2017, 119, 440-444.                         | 1.6  | 21        |
| 807 | Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1248-1258. | 7.1  | 21        |
| 808 | N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019, 12, e005766.   | 3.9  | 21        |
| 809 | Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. <i>American Heart Journal</i> , 2020, 222, 157-165.  | 2.7  | 21        |
| 810 | Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.   | 8.6  | 21        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 811 | Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in AHFpEF. JACC: Heart Failure, 2021, 9, 627-635.   | 4.1  | 21        |
| 812 | Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008837. | 3.9  | 21        |
| 813 | Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 504-510.  | 2.8  | 21        |
| 814 | Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the <sc>EMPEROR</sc> Preserved trial. European Journal of Heart Failure, 2022, 24, 1869-1878.  | 7.1  | 21        |
| 815 | Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction. Cardiovascular Research, 1998, 39, 563-570.  | 3.8  | 20        |
| 816 | Prognostic impact of pulmonary arterial hypertension: A population-based analysis. International Journal of Cardiology, 2008, 124, 183-187.  | 1.7  | 20        |
| 817 | Biomarkers in heart failure: a clinical review. Heart Failure Reviews, 2010, 15, 251-273.  | 3.9  | 20        |
| 818 | Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. European Journal of Neurology, 2015, 22, 163-169.   | 3.3  | 20        |
| 819 | Barcelona BioHF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. European Journal of Heart Failure, 2018, 20, 938-940.                         | 7.1  | 20        |
| 820 | Systolic blood pressure reduction during the first 24h in acute heart failure admission: friend or foe?. European Journal of Heart Failure, 2018, 20, 317-322.   | 7.1  | 20        |
| 821 | Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 1022-1031.   | 7.1  | 20        |
| 822 | Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 418-427.  | 4.1  | 20        |
| 823 | Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care, 2020, 43, 2878-2881.   | 8.6  | 20        |
| 824 | Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. Journal of the American Heart Association, 2021, 10, e019238.        | 3.7  | 20        |
| 825 | Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <sc>PARADIGM-HF</sc> trial. European Journal of Heart Failure, 2021, 23, 1518-1524.  | 7.1  | 20        |
| 826 | Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in <sc>PARADIGM-HF</sc>. European Journal of Heart Failure, 2022, 24, 551-561.   | 7.1  | 20        |
| 827 | Calcium-antagonist controversy: the long and short of it?. Lancet, The, 1997, 349, 585-586.  | 13.7 | 19        |
| 828 | Monocyte chemoattractant protein-1: A dichotomous role in cardiac remodeling following acute myocardial infarction in man?. Cytokine, 2010, 50, 158-162.   | 3.2  | 19        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 829 | Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure, 2011, 13, 755-764. | 7.1 | 19        |
| 830 | Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. European Heart Journal, 2012, 33, 1049-1057.   | 2.2 | 19        |
| 831 | Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: Impact on general and mental health, quality of life and five-year mortality. International Journal of Cardiology, 2013, 167, 2149-2155.            | 1.7 | 19        |
| 832 | The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27,610 patients. European Journal of Heart Failure, 2014, 16, 289-299.   | 7.1 | 19        |
| 833 | Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). PLoS ONE, 2015, 10, e0133970.  | 2.5 | 19        |
| 834 | Telomere length and outcomes in ischaemic heart failure: data from the Controlled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA). European Journal of Heart Failure, 2015, 17, 313-319.   | 7.1 | 19        |
| 835 | Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 777-785.  | 4.1 | 19        |
| 836 | Mind the Gap: Current Challenges and Future State of Heart Failure Care. Canadian Journal of Cardiology, 2017, 33, 1434-1449.   | 1.7 | 19        |
| 837 | Real World Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry. Cardiovascular Drugs and Therapy, 2019, 33, 315-322.  | 2.6 | 19        |
| 838 | Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. European Journal of Heart Failure, 2020, 22, 1402-1411.          | 7.1 | 19        |
| 839 | Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiology, 2021, 6, 1415.   | 6.1 | 19        |
| 840 | Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008597.  | 3.9 | 19        |
| 841 | Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Journal of Cardiac Failure, 2022, 28, 1050-1062.  | 1.7 | 19        |
| 842 | Synergism of histidyl dipeptides as antioxidants. Journal of Molecular and Cellular Cardiology, 1991, 23, 1205-1207.  | 1.9 | 18        |
| 843 | Clinical experience with endothelin receptor antagonists in chronic heart failure. Heart Failure Reviews, 2001, 6, 317-323.   | 3.9 | 18        |
| 844 | Digitalis for treatment of heart failure in patients in sinus rhythm. , 2004, , CD002901.   |     | 18        |
| 845 | Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger. European Heart Journal, 2006, 27, 2257-2259.  | 2.2 | 18        |
| 846 | Transthoracic echocardiography: a survey of current practice in the UK. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 345-349.   | 0.5 | 18        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 847 | Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction. <i>Circulation</i> , 2011, 123, 2674-2680.   | 1.6  | 18        |
| 848 | Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2014, 35, 3426-3433. | 2.2  | 18        |
| 849 | The Aliskiren Trial to Minimize <scp>OutcomeS</scp> in Patients with <scp>HEart</scp> failure trial (<scp>ATMOSPHERE</scp>): revised statistical analysis plan and baseline characteristics. <i>European Journal of Heart Failure</i> , 2015, 17, 1075-1083.   | 7.1  | 18        |
| 850 | Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 618-625.  | 4.1  | 18        |
| 851 | Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. <i>JAMA Cardiology</i> , 2017, 2, 525.  | 6.1  | 18        |
| 852 | Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <scp>ATMOSPHERE</scp> trial. <i>European Journal of Heart Failure</i> , 2018, 20, 136-147.    | 7.1  | 18        |
| 853 | Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. <i>Korean Circulation Journal</i> , 2019, 49, 469.   | 1.9  | 18        |
| 854 | Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.                 | 1.9  | 18        |
| 855 | Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.                               | 1.6  | 18        |
| 856 | Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 336-346.   | 4.1  | 18        |
| 857 | Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. <i>BMJ</i> , The, 0, , e068424.   | 6.0  | 18        |
| 858 | Consequences of fluid loss in patients treated with ACE inhibitors.. <i>Postgraduate Medical Journal</i> , 1987, 63, 385-387.  | 1.8  | 17        |
| 859 | Circulating Endothelin Is Not Extracted by the Pulmonary Circulation in Man. <i>Chest</i> , 1992, 102, 1143-1144.  | 0.8  | 17        |
| 860 | A Qualitative Study of the Contribution of Pharmacists to Heart Failure Management in Scotland. <i>International Journal of Clinical Pharmacy</i> , 2005, 27, 453-458.   | 1.4  | 17        |
| 861 | Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. <i>American Heart Journal</i> , 2011, 161, 1156-1162.                             | 2.7  | 17        |
| 862 | Plasma TIMP-4 Predicts Left Ventricular Remodeling After Acute Myocardial Infarction. <i>Journal of Cardiac Failure</i> , 2011, 17, 465-471.   | 1.7  | 17        |
| 863 | Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (â€PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.                                | 7.1  | 17        |
| 864 | Clinical Trials Series. <i>New England Journal of Medicine</i> , 2016, 374, 2167-2167.   | 27.0 | 17        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 865 | Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. <i>Heart</i> , 2017, 103, 55-62.  | 2.9 | 17        |
| 866 | New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.  | 7.1 | 17        |
| 867 | Heart Failure. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 117-135.  | 3.2 | 17        |
| 868 | Microvascular complications in diabetes patients with heart failure and reduced ejection fraction—insights from the Beta-blocker Evaluation of Survival Trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1549-1556.  | 7.1 | 17        |
| 869 | Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. <i>Clinical Research in Cardiology</i> , 2019, 108, 1215-1225. | 3.3 | 17        |
| 870 | Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.   | 4.1 | 17        |
| 871 | Body mass index and ß-tines on lung ultrasonography in chronic and acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1201-1209.  | 3.1 | 17        |
| 872 | Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.  | 4.1 | 17        |
| 873 | Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. <i>Circulation</i> , 2022, 145, 1741-1743.   | 1.6 | 17        |
| 874 | Alteration of the erythrocyte glutathione redox balance by N-acetylcysteine, captopril and exogenous glutathione. <i>FEBS Letters</i> , 1994, 347, 215-220.   | 2.8 | 16        |
| 875 | Analysis of reproducibility of reference lumen quantitation with intravascular ultrasound in stented coronary arteries. , 1997, 40, 1-7.  |     | 16        |
| 876 | Are angiotensin ii receptor blockers more efficacious than placebo in heart failure? implications of elite-2. <i>American Journal of Cardiology</i> , 2001, 87, 606-607.  | 1.6 | 16        |
| 877 | Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1865-1871.   | 2.8 | 16        |
| 878 | An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. <i>European Journal of Heart Failure</i> , 2010, 12, 66-74.   | 7.1 | 16        |
| 879 | B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway?. <i>Diabetologia</i> , 2012, 55, 1240-1243.  | 6.3 | 16        |
| 880 | CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , 2013, 15, 747-755.   | 7.1 | 16        |
| 881 | Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2015, 17, 707-716.   | 7.1 | 16        |
| 882 | Predictive Value of Endostatin in Chronic Heart Failure Patients with Poor Kidney Function. <i>Cardiology</i> , 2015, 130, 17-22.   | 1.4 | 16        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 883 | Clinical characteristics and outcomes of patients with angina and heart failure in the <scp>CHARM</scp> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq1 1 0.784314 ngBT /Overclock 10 T   | 7.1 | 16        |
| 884 | Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure. European Journal of Heart Failure, 2018, 20, 240-247.  | 7.1 | 16        |
| 885 | Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). American Journal of Cardiology, 2018, 122, 1506-1512.  | 1.6 | 16        |
| 886 | Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure, 2020, 22, 1133-1143.   | 7.1 | 16        |
| 887 | Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. Journal of Cardiac Failure, 2021, 27, 670-676.   | 1.7 | 16        |
| 888 | Reâ€examining the widespread policy of stopping sodiumâ€glucose cotransporterâ€2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 2022, 24, 2071-2080.  | 4.4 | 16        |
| 889 | Neuroendocrine changes post myocardial infarction: Effects of xamoterol. American Heart Journal, 1990, 120, 56-62.   | 2.7 | 15        |
| 890 | Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease. European Journal of Heart Failure, 1999, 1, 297-300.  | 7.1 | 15        |
| 891 | Venous endothelin receptor function in patients with chronic heart failure. Clinical Science, 2000, 98, 65-70.   | 4.3 | 15        |
| 892 | It cannot be cardiac failure because the heart is not enlarged on the chest X-ray. European Journal of Heart Failure, 2003, 5, 117-119.  | 7.1 | 15        |
| 893 | Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). American Journal of Cardiology, 2009, 104, 151-157.  | 1.6 | 15        |
| 894 | Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure â€“ Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 2010, 12, 738-745.                | 7.1 | 15        |
| 895 | Digitalis for treatment of heart failure in patients in sinus rhythm. The Cochrane Library, 2014, , CD002901.  | 2.8 | 15        |
| 896 | It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD?. European Heart Journal, 2015, 36, 2047-2049.   | 2.2 | 15        |
| 897 | ESRD After Heart Failure, Myocardial Infarction, or Stroke in TypeÂ2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 2017, 70, 522-531.   | 1.9 | 15        |
| 898 | Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1560-1562.  | 1.6 | 15        |
| 899 | Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes. Circulation, 2018, 137, 1218-1220.  | 1.6 | 15        |
| 900 | Post hoc analyses of SHIFT and PARADIGMâ€HF highlight the importance of chronic Chagas' cardiomyopathy <i>Comment on:</i> â€œSafety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trialâ€by Bocchi <i>et al.</i>. ESC Heart Failure, 2018, 5, 1069-1071. | 3.1 | 15        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 901 | Estimating the Lifetime Benefits of Treatments for Heart Failure. JACC: Heart Failure, 2020, 8, 984-995.  | 4.1  | 15        |
| 902 | The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 2020, 7, 1595-1604.  | 3.1  | 15        |
| 903 | Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e022069.  | 3.7  | 15        |
| 904 | Winter Peaks in Heart Failure: An Inevitable or Preventable Consequence of Seasonal Vulnerability?. Cardiac Failure Review, 2019, 5, 83-85.   | 3.0  | 15        |
| 905 | Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in <sc>Denmark</sc> from 2003 to 2017. European Journal of Heart Failure, 2022, 24, 539-547. | 7.1  | 15        |
| 906 | Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from <sc>PARAGON-HF</sc>. European Journal of Heart Failure, 2022, 24, 794-803.     | 7.1  | 15        |
| 907 | Re-emergence of heart failure with a normal ejection fraction?. European Heart Journal, 2022, 43, 427-429.  | 2.2  | 15        |
| 908 | Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 5006-5016.  | 2.2  | 15        |
| 909 | EFFECT OF DIARRHOEA ON A PATIENT TAKING CAPTOPRIL. Lancet, The, 1985, 325, 581.   | 13.7 | 14        |
| 910 | Atrial natriuretic factor inhibits ACTH stimulated aldosterone, but not cortisol, secretion in man. European Journal of Clinical Pharmacology, 1988, 35, 409-412.   | 1.9  | 14        |
| 911 | Angiotensin inhibition in heart failure.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, S17.  | 1.7  | 14        |
| 912 | Increasing Awareness and Perception of Heart Failure in Europe and Improving Care: Rationale and Design of the SHAPE Study. Cardiovascular Drugs and Therapy, 2004, 18, 153-159.  | 2.6  | 14        |
| 913 | Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel?. European Journal of Heart Failure, 2013, 15, 5-8.  | 7.1  | 14        |
| 914 | Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. International Journal of Cardiology, 2014, 177, 840-846.   | 1.7  | 14        |
| 915 | Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction) Tj ETQq1 1 0.784314rgBT /Overlock 10                           | 1.7  | 14        |
| 916 | Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.              | 7.1  | 14        |
| 917 | Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. Circulation: Heart Failure, 2020, 13, e007879.  | 3.9  | 14        |
| 918 | Cardiorenal risk reduction guidance in diabetes: can we reach consensus?. Lancet Diabetes and Endocrinology, the, 2020, 8, 357-360.   | 11.4 | 14        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 919 | Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. <i>European Journal of Heart Failure</i> , 2020, 22, 848-855.  | 7.1 | 14        |
| 920 | Quantification of pleural effusions on thoracic ultrasound in acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 513-521.  | 1.0 | 14        |
| 921 | <sc>SOLOIST&WHLF</sc> and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 27-30.                           | 7.1 | 14        |
| 922 | Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. <i>Circulation</i> , 2021, 143, 2316-2318.   | 1.6 | 14        |
| 923 | <sc>Angiotensin&neprilysin</sc> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.   | 7.1 | 14        |
| 924 | Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. <i>Cardiovascular Diabetology</i> , 2022, 21, .  | 6.8 | 14        |
| 925 | Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2001, 3, 249-255.   | 7.1 | 13        |
| 926 | Carvedilol reduces the costs of medical care in severe heart failure: An economic analysis of the COPERNICUS study applied to the United Kingdom. <i>International Journal of Cardiology</i> , 2005, 100, 143-149.   | 1.7 | 13        |
| 927 | Cardiac and Extracardiac Abnormalities Detected by Cardiac Magnetic Resonance in a Post-Myocardial Infarction Cohort. <i>Cardiology</i> , 2009, 113, 1-8.  | 1.4 | 13        |
| 928 | What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?. <i>Open Heart</i> , 2015, 2, e000283.   | 2.3 | 13        |
| 929 | Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the <sc>NAVIGATOR</sc> trial. <i>Diabetic Medicine</i> , 2015, 32, 1090-1096.   | 2.3 | 13        |
| 930 | Site selection for heart failure clinical trials in the USA. <i>Heart Failure Reviews</i> , 2015, 20, 375-383.   | 3.9 | 13        |
| 931 | Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia&the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). <i>Journal of Human Hypertension</i> , 2016, 30, 46-52. | 2.2 | 13        |
| 932 | Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). <i>Circulation: Heart Failure</i> , 2018, 11, e004431.                                      | 3.9 | 13        |
| 933 | Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. <i>Diabetologia</i> , 2018, 61, 581-588.  | 6.3 | 13        |
| 934 | Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008052.   | 3.9 | 13        |
| 935 | Haemodynamic effects of the nitroxyl donor cimlanod (<sc>BMS</sc>â&986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1147-1155.   | 7.1 | 13        |
| 936 | Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON&HF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.   | 3.7 | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 937 | Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. <i>Kidney International</i> , 2005, 68, 1419-1426.  | 5.2 | 12        |
| 938 | Aspirin Inhibits the Acute Arterial and Venous Vasodilator Response to Captopril in Patients with Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 261-265.  | 2.6 | 12        |
| 939 | Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?. <i>Circulation</i> , 2006, 113, 2566-2568.   | 1.6 | 12        |
| 940 | Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II). <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 77-85.   | 2.6 | 12        |
| 941 | Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 1253-1261.  | 7.1 | 12        |
| 942 | Novel Extracellular Matrix Biomarkers as Predictors of Adverse Outcome in Chronic Heart Failure: Association Between Biglycan and Response to Statin Therapy in the CORONA Trial. <i>Journal of Cardiac Failure</i> , 2015, 21, 153-159.                               | 1.7 | 12        |
| 943 | Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .   | 3.9 | 12        |
| 944 | Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. <i>European Journal of Heart Failure</i> , 2016, 18, 1175-1181. | 7.1 | 12        |
| 945 | Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. <i>JACC: Heart Failure</i> , 2017, 5, 591-599.   | 4.1 | 12        |
| 946 | Optimizing heart failure treatment following cardiac resynchronization therapy. <i>Clinical Research in Cardiology</i> , 2020, 109, 638-645.   | 3.3 | 12        |
| 947 | Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , 2020, 38, 420-425.                | 0.5 | 12        |
| 948 | Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 296-301.                              | 3.0 | 12        |
| 949 | Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 776-784.   | 7.1 | 12        |
| 950 | Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.  | 6.1 | 12        |
| 951 | Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 165-168.   | 2.4 | 11        |
| 952 | The year in heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2398-2405.   | 2.8 | 11        |
| 953 | Heart Failure Management Programs Reduce Readmissions and Prolong Survival. <i>Archives of Internal Medicine</i> , 2005, 165, 1311.  | 3.8 | 11        |
| 954 | Dysglycemia and Heart Failure Hospitalization. <i>Circulation</i> , 2007, 115, 1334-1335.  | 1.6 | 11        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 955 | Dual Renin-Angiotensin System Blockade and Kidney Disease. Journal of the American College of Cardiology, 2009, 54, 278-279.   | 2.8 | 11        |
| 956 | Evaluating dyspnoea in acute heart failure: progress at last!. European Heart Journal, 2010, 31, 771-772.  | 2.2 | 11        |
| 957 | The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. European Journal of Heart Failure, 2011, 13, 917-924.   | 7.1 | 11        |
| 958 | Gut Feelings About Heart Failure— Journal of the American College of Cardiology, 2014, 64, 1915-1916.  | 2.8 | 11        |
| 959 | Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. International Journal of Cardiology, 2014, 176, 1126-1128.   | 1.7 | 11        |
| 960 | High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study. Journal of Cardiac Failure, 2019, 25, 230-237.  | 1.7 | 11        |
| 961 | Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. Journal of Cardiac Failure, 2019, 25, 703-711.                                      | 1.7 | 11        |
| 962 | Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2019, 108, 868-877.  | 3.3 | 11        |
| 963 | The year in cardiology: heart failure. European Heart Journal, 2020, 41, 1232-1248.  | 2.2 | 11        |
| 964 | Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 2020, 109, 1358-1365.  | 3.3 | 11        |
| 965 | Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.               | 7.1 | 11        |
| 966 | Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy. JACC: Heart Failure, 2021, 9, 386-397.   | 4.1 | 11        |
| 967 | The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.   | 3.1 | 11        |
| 968 | The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1824-1832.   | 4.5 | 11        |
| 969 | Health Status Trajectories Before and After Hospitalization for Heart Failure. Circulation, 2022, 145, 1872-1874.  | 1.6 | 11        |
| 970 | Final Consensus Statement of the Royal College of Physicians of Edinburgh Consensus Conference on Atrial Fibrillation in Hospital and General Practice, 3-4 September 1998. British Journal of Haematology, 1999, 104, 195-196.        | 2.5 | 10        |
| 971 | Geographic variation in the treatment of acute myocardial infarction in the VALSartan In Acute myocardial infarction (VALIANT) trial. American Heart Journal, 2006, 152, 500-508.  | 2.7 | 10        |
| 972 | Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials. Cardiovascular Therapeutics, 2010, 28, 124-132. | 2.5 | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 973 | Interleukin-21 “ A biomarker of importance in predicting myocardial function following acute infarction?. Cytokine, 2012, 60, 220-225.   | 3.2 | 10        |
| 974 | Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure. Journal of Hypertension, 2018, 36, 1736-1742.                             | 0.5 | 10        |
| 975 | Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. Clinical Epidemiology, 2018, Volume 10, 917-930.   | 3.0 | 10        |
| 976 | N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes, Obesity and Metabolism, 2018, 20, 2899-2904.                                    | 4.4 | 10        |
| 977 | Baseline Characteristics of the VANISH Cohort. Circulation: Heart Failure, 2019, 12, e006231.  | 3.9 | 10        |
| 978 | Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure. Circulation: Heart Failure, 2020, 13, e008007.  | 3.9 | 10        |
| 979 | Response by Jackson et al to Letter Regarding Article, “Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF”. Circulation, 2020, 142, e5-e6.                      | 1.6 | 10        |
| 980 | Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the <scp>SONAR</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 561-568.                            | 4.4 | 10        |
| 981 | Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation, 2022, 37, 960-972.   | 0.7 | 10        |
| 982 | The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (<scp>COSMIC</scp> “<scp>HF</scp>”). European Journal of Heart Failure, 2021, 23, 1052-1056.                             | 7.1 | 10        |
| 983 | Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. International Journal of Cardiology, 2021, 330, 91-97. | 1.7 | 10        |
| 984 | Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure, 2022, 10, 52-64.   | 4.1 | 10        |
| 985 | Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 2212-2220.  | 2.2 | 10        |
| 986 | Relationship of Dapagliflozin With Serum Sodium. JACC: Heart Failure, 2022, 10, 306-318.   | 4.1 | 10        |
| 987 | Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, .  |     | 10        |
| 988 | The reproducibility of symptoms during a submaximal exercise test in chronic heart failure. British Journal of Clinical Pharmacology, 1998, 45, 287-290.   | 2.4 | 9         |
| 989 | Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin-1. European Journal of Heart Failure, 1999, 1, 25-29.   | 7.1 | 9         |
| 990 | Effect of Rosuvastatin on Fatigue in Patients With Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1121-1122.  | 2.8 | 9         |

| #    | ARTICLE  | IF   | CITATIONS |
|------|--|------|-----------|
| 991  | Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. European Heart Journal, 2013, 34, 1621-1629.   | 2.2  | 9         |
| 992  | ECG “ Still the Best for Selecting Patients for CRT. New England Journal of Medicine, 2013, 369, 1463-1464.  | 27.0 | 9         |
| 993  | Î² blockers, atrial fibrillation, and heart failure. Lancet, The, 2014, 384, 2181-2183.  | 13.7 | 9         |
| 994  | The association between meteorological events and acute heart failure: New insights from ASCEND-HF. International Journal of Cardiology, 2014, 177, 819-824.   | 1.7  | 9         |
| 995  | Venous Thromboembolism and Cardiovascular Risk: Results from the NAVIGATOR Trial. American Journal of Medicine, 2015, 128, 297-302.  | 1.5  | 9         |
| 996  | Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. Journal of Cardiac Failure, 2016, 22, 409-416.         | 1.7  | 9         |
| 997  | Clinical Trials Involving Hypertension. New England Journal of Medicine, 2017, 376, 289-290.   | 27.0 | 9         |
| 998  | Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2018, 24, 512-519.                                       | 1.7  | 9         |
| 999  | Redefining heart failure phenotypes based on ejection fraction. European Journal of Heart Failure, 2018, 20, 1634-1635.  | 7.1  | 9         |
| 1000 | Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 2019, 281, 179-185.   | 1.7  | 9         |
| 1001 | Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. ESC Heart Failure, 2020, 7, 3355-3364.  | 3.1  | 9         |
| 1002 | Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure. Circulation: Heart Failure, 2020, 13, e007814.  | 3.9  | 9         |
| 1003 | Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 2021, 8, 129-138.   | 3.1  | 9         |
| 1004 | Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <sc>HEAAL</sc> trial. European Journal of Heart Failure, 2021, 23, 1477-1484.  | 7.1  | 9         |
| 1005 | Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. JACC: Heart Failure, 2021, 9, 518-527.  | 4.1  | 9         |
| 1006 | Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 2900-2911. | 6.1  | 9         |
| 1007 | Drug therapy for heart failure with reduced ejection fraction: what is the “right” dose?. European Journal of Heart Failure, 2022, 24, 421-430.  | 7.1  | 9         |
| 1008 | Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. Clinical Science, 2001, 101, 45.  | 4.3  | 8         |

| #    | ARTICLE  | IF   | CITATIONS |
|------|--|------|-----------|
| 1009 | Effect of Neutral Endopeptidase Inhibition on the Actions of Adrenomedullin and Endothelin-1 in Resistance Arteries From Patients With Chronic Heart Failure. <i>Hypertension</i> , 2001, 38, 412-416.   | 2.7  | 8         |
| 1010 | The statin wars. <i>Lancet</i> , The, 2003, 362, 1854.   | 13.7 | 8         |
| 1011 | Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2004, 57, 1213-1232.   | 1.2  | 8         |
| 1012 | Predictors of Stroke in Patients With Impaired Glucose Tolerance. <i>Stroke</i> , 2013, 44, 2590-2593.   | 2.0  | 8         |
| 1013 | Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). <i>Biomarkers</i> , 2017, 22, 261-267.   | 1.9  | 8         |
| 1014 | Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017, 46, 488-497.                     | 3.1  | 8         |
| 1015 | Cost-Effectiveness Analysis of Natriuretic Peptide Testing and Specialist Management in Patients with Suspected Acute Heart Failure. <i>Value in Health</i> , 2017, 20, 1025-1033.   | 0.3  | 8         |
| 1016 | Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2021, 110, 1234-1248.   | 3.3  | 8         |
| 1017 | Captopril and Norepinephrine-Induced Hypertrophy and Haemodynamics in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 27, 667-672.   | 1.9  | 8         |
| 1018 | Qu3telet (body mass) index and effects of dapagliflozin in chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 827-837.  | 4.4  | 8         |
| 1019 | Unique cardioprotective potential of angiotensin converting enzyme inhibitors: a hypothesis still to be tested on humans. <i>Journal of Hypertension</i> , 1991, 9, 393-397.   | 0.5  | 7         |
| 1020 | ACE inhibitors and health-care economics. <i>Coronary Artery Disease</i> , 1995, 6, 315-320.   | 0.7  | 7         |
| 1021 | Cardiac cachexia3lean and mean. <i>European Heart Journal</i> , 1999, 20, 1609-1611.   | 2.2  | 7         |
| 1022 | Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. <i>Clinical Science</i> , 2001, 101, 45-51. | 4.3  | 7         |
| 1023 | Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 37-42.  | 2.4  | 7         |
| 1024 | Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?. <i>European Heart Journal</i> , 2004, 25, 357-358.   | 2.2  | 7         |
| 1025 | A putative placebo comparison of the SCOPE and LIFE trials. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, 59-63.   | 1.7  | 7         |
| 1026 | Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. <i>Country Review Ukraine</i> , 2005, 7, C41-C54.   | 0.8  | 7         |

| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1027 | Angiotensin receptor blockers and myocardial infarction. BMJ: British Medical Journal, 2005, 330, 1269.1.   | 2.3  | 7         |
| 1028 | Calcium Handling in the Failing Heart and SUMO – Weighing the Evidence. New England Journal of Medicine, 2011, 365, 1738-1739.  | 27.0 | 7         |
| 1029 | Clinical Outcomes at 180 days in the ASCEND-HF Trial: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure. Journal of Cardiac Failure, 2011, 17, 971.  | 1.7  | 7         |
| 1030 | Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine, 2013, 369, 487-489.  | 27.0 | 7         |
| 1031 | Why and when should we worry about worsening renal function?. European Journal of Heart Failure, 2014, 16, 4-5.   | 7.1  | 7         |
| 1032 | Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 2015, 5, e007901.  | 1.9  | 7         |
| 1033 | Effect of valsartan on kidney outcomes in people with impaired glucose tolerance. Diabetes, Obesity and Metabolism, 2017, 19, 791-799.  | 4.4  | 7         |
| 1034 | Lung ultrasound: monitoring congestion in patients with heart failure. European Journal of Heart Failure, 2019, 21, 1614-1615.  | 7.1  | 7         |
| 1035 | The importance of randomised vs non-randomised trials – Authors' reply. Lancet, The, 2019, 394, 635.  | 13.7 | 7         |
| 1036 | Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 2019, 21, 699-702.  | 7.1  | 7         |
| 1037 | EMPEROR – Reduced: confirming sodium–glucose co-transporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1987-1990.  | 7.1  | 7         |
| 1038 | High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 2023, 119, 213-220.   | 3.8  | 7         |
| 1039 | Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 2021, 8, 1784-1795.  | 3.1  | 7         |
| 1040 | Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 2022, 24, 529-538.   | 7.1  | 7         |
| 1041 | Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2021, 2, 10.34067/KID.0004272021.   | 2.1  | 7         |
| 1042 | Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 750-760.   | 4.0  | 7         |
| 1043 | Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 2022, 24, 861-866. | 7.1  | 7         |
| 1044 | Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 2022, 45, .   | 1.8  | 7         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1045 | Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score. JACC: Heart Failure, 2022, 10, 543-555.  | 4.1 | 7         |
| 1046 | Furosemide pretreatment blunts the inhibition of renal tubular sodium reabsorption by ANF in man. European Journal of Clinical Pharmacology, 1988, 35, 333-338.   | 1.9 | 6         |
| 1047 | Endothelin Receptor Antagonists and Cardiovascular Diseases of Aging. Drugs and Aging, 2001, 18, 425-439.   | 2.7 | 6         |
| 1048 | Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. Cardiovascular Drugs and Therapy, 2011, 25, 315-321.  | 2.6 | 6         |
| 1049 | Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 2015, 15, 3.                              | 1.8 | 6         |
| 1050 | Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial. Journal of Cardiac Failure, 2015, 21, S9-S10.  | 1.7 | 6         |
| 1051 | T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. Clinical Research in Cardiology, 2019, 108, 133-141.                    | 3.3 | 6         |
| 1052 | Estimated Long-Term Survival With Eplerenone. Journal of the American College of Cardiology, 2019, 73, 2357-2359.   | 2.8 | 6         |
| 1053 | Do We Need Clinical Events Committees to Adjudicate End Points?. Circulation: Heart Failure, 2020, 13, e007209.   | 3.9 | 6         |
| 1054 | Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease. European Journal of Heart Failure, 2020, 22, 813-820.   | 7.1 | 6         |
| 1055 | Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure. Journal of Cardiac Failure, 2021, 27, 693-695.  | 1.7 | 6         |
| 1056 | Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 227-235.  | 3.0 | 6         |
| 1057 | Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. European Journal of Heart Failure, 2022, 24, 672-677.   | 7.1 | 6         |
| 1058 | Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. Kidney International Reports, 2022, 7, 699-707.  | 0.8 | 6         |
| 1059 | Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". Circulation, 2021, 144, e40. | 1.6 | 6         |
| 1060 | Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. American Heart Journal, 2022, 251, 13-24.   | 2.7 | 6         |
| 1061 | Elevated serum and monocyte tumour necrosis factor alpha in patients with congestive heart failure. International Journal of Cardiology, 1999, 71, 263-264.   | 1.7 | 5         |
| 1062 | Angiotensin receptor blockers in heart failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 171-175.  | 1.7 | 5         |



| #    | ARTICLE  | IF   | CITATIONS |
|------|--|------|-----------|
| 1063 | EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE. Rational Pharmacotherapy in Cardiology, 2005, 1, 49-69.   | 0.8  | 5         |
| 1064 | Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 128-129.                                  | 3.3  | 5         |
| 1065 | QRS duration alone to select patients for cardiac resynchronization therapy: flying in the face of the evidence?. European Heart Journal, 2006, 27, 3074-3075.   | 2.2  | 5         |
| 1066 | HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure—lessons learnt from a decade of trials. European Journal of Heart Failure, 2010, 12, 99-103.                                     | 7.1  | 5         |
| 1067 | Prediabetes and the risk of diabetes. Lancet, The, 2012, 380, 1225-1226.   | 13.7 | 5         |
| 1068 | The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. Journal of Cardiac Failure, 2012, 18, 883.                               | 1.7  | 5         |
| 1069 | A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. American Journal of Cardiology, 2013, 112, 231-237.  | 1.6  | 5         |
| 1070 | Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. European Journal of Heart Failure, 2013, 15, 1205-1207.  | 7.1  | 5         |
| 1071 | Updated risk factors should be used to predict development of diabetes. Journal of Diabetes and Its Complications, 2017, 31, 859-863.  | 2.3  | 5         |
| 1072 | Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal, 2018, 199, 170-175.  | 2.7  | 5         |
| 1073 | Who Benefits From a Defibrillator—Balancing the Risk of Sudden Versus Non-sudden Death. Current Heart Failure Reports, 2018, 15, 376-389.  | 3.3  | 5         |
| 1074 | Talking to patients with heart failure about end of life. European Journal of Heart Failure, 2018, 20, 1763-1765.  | 7.1  | 5         |
| 1075 | Prognostic Modeling in Heart Failure. JACC: Heart Failure, 2018, 6, 463-464.   | 4.1  | 5         |
| 1076 | Only Trials Tell the Truth About Treatment Effects. Journal of the American College of Cardiology, 2018, 71, 2640-2642.  | 2.8  | 5         |
| 1077 | Phosphodiesterase-9 Inhibition in Heart Failure. Journal of the American College of Cardiology, 2019, 74, 902-904.   | 2.8  | 5         |
| 1078 | Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. Clinical Research in Cardiology, 2019, 108, 806-814.                                     | 3.3  | 5         |
| 1079 | Chagas disease: still a neglected emergency?. Lancet, The, 2020, 395, 1113-1114.   | 13.7 | 5         |
| 1080 | Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacology and Therapeutics, 2021, 109, 1631-1638. | 4.7  | 5         |

| #    | ARTICLE  | IF   | CITATIONS |
|------|--|------|-----------|
| 1081 | Influence of Study Discontinuation during the Run-in Period on the Estimated Efficacy of Sacubitril/valsartan in the PARAGON-HF Trial. <i>European Journal of Heart Failure</i> , 2021, , .  | 7.1  | 5         |
| 1082 | Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure. <i>CJC Open</i> , 2020, 2, 135-144.   | 1.5  | 5         |
| 1083 | Clinical Trials Report: Cardiovascular & Renal: Ongoing and planned clinical trials in chronic heart failure and left ventricular dysfunction. <i>Expert Opinion on Investigational Drugs</i> , 1995, 4, 1069-1080.  | 4.1  | 5         |
| 1084 | Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in ADAPA-HF. <i>JACC: Heart Failure</i> , 2022, 10, 104-118.  | 4.1  | 5         |
| 1085 | Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2022, 11, e021327. | 3.7  | 5         |
| 1086 | The ASCEND-ND trial: study design and participant characteristics. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2157-2170.   | 0.7  | 5         |
| 1087 | Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish AHF Registry. <i>JACC: Heart Failure</i> , 2022, 10, 380-392.   | 4.1  | 5         |
| 1088 | Beta-blockers, ventricular arrhythmias, and sudden death in heart failure: not as simple as it seems. <i>European Heart Journal</i> , 2000, 21, 1214-1215.   | 2.2  | 4         |
| 1089 | Myocardial Infarct. <i>Circulation</i> , 2002, 105, 2577-2579.   | 1.6  | 4         |
| 1090 | The CHARM programme. <i>Lancet</i> , The, 2003, 362, 1678-1679.  | 13.7 | 4         |
| 1091 | Aldosterone blockade in post-acute myocardial infarction heart failure. <i>Clinical Cardiology</i> , 2006, 29, 434-438.  | 1.8  | 4         |
| 1092 | Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. <i>European Journal of Heart Failure</i> , 2009, 11, 110-110.                                      | 7.1  | 4         |
| 1093 | 'Iron deficiency: an ominous sign in patients with systolic chronic heart failure' [Eur Heart J 2010;31:1872-1880, doi:10.1093/eurheartj/ehq158]. <i>European Heart Journal</i> , 2011, 32, 1054-1054.   | 2.2  | 4         |
| 1094 | Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 4427-4429.  | 1.7  | 4         |
| 1095 | Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .  | 3.7  | 4         |
| 1096 | Aliskiren, Enalapril, or Both in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 375, 701-702.   | 27.0 | 4         |
| 1097 | Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2488-2490.  | 2.8  | 4         |
| 1098 | The Effect of Omecamtiv Mecarbil on Symptoms of Heart Failure in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF). <i>Journal of Cardiac Failure</i> , 2016, 22, S10-S11.  | 1.7  | 4         |

| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1099 | International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. Journal of the American Heart Association, 2017, 6, .  | 3.7  | 4         |
| 1100 | EFFECT OF SACUBITRIL/VALSARTAN COMPARED WITH ENALAPRIL, ACCORDING TO ETIOLOGY IN PARADIGM-HF. Journal of the American College of Cardiology, 2017, 69, 919.   | 2.8  | 4         |
| 1101 | Effects of apixaban compared with warfarin as gain in event-free time â€“ a novel assessment of the results of the ARISTOTLE trial. European Journal of Preventive Cardiology, 2020, 27, 1311-1319.                                   | 1.8  | 4         |
| 1102 | Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. Diabetes Research and Clinical Practice, 2020, 170, 108488. | 2.8  | 4         |
| 1103 | Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology, 2021, 110, 1334-1349.                      | 3.3  | 4         |
| 1104 | Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. Clinical Research in Cardiology, 2021, 111, 440.                               | 3.3  | 4         |
| 1105 | Concise Guide to the Management of Heart Failure - World Health Organization/Council on Geriatric Cardiology Task Force on Heart Failure Education. The American Journal of Geriatric Cardiology, 1996, 5, 13-30.                     | 0.6  | 4         |
| 1106 | Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC: Heart Failure, 2022, 10, 415-427.  | 4.1  | 4         |
| 1107 | Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With IncidentÂHeartÂFailure. JACC: Heart Failure, 2022, 10, 498-507.   | 4.1  | 4         |
| 1108 | Factors associated with healthâ€related quality of life in heart failure in 23,000 patients from 40 countries: Results of the <sc>Gâ€CHF</sc> Research Program. European Journal of Heart Failure, 2022, , .                          | 7.1  | 4         |
| 1109 | The J-curve hypothesis. Lancet, The, 1992, 339, 561-562.  | 13.7 | 3         |
| 1110 | ACE inhibitors for myocardial infarction and unstable angina. Lancet, The, 1992, 340, 1547-1549.  | 13.7 | 3         |
| 1111 | Effects of the xanthine oxidase system on cardiac function in anaesthetised rats. Free Radical Biology and Medicine, 1993, 15, 249-255.   | 2.9  | 3         |
| 1112 | ACE Inhibitors after myocardial Infarction. Lancet, The, 1993, 342, 1418-1419.  | 13.7 | 3         |
| 1113 | EARTH: Endothelin<sub>A</sub> Receptor Antagonist Trial in Heart Failure. Cardiology, 2001, 1, 294-298.   | 0.3  | 3         |
| 1114 | Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, 89-92.                                | 1.7  | 3         |
| 1115 | Beta-blockers and heart failure in older people: reply. European Heart Journal, 2006, 27, 888-889.  | 2.2  | 3         |
| 1116 | Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports, 2009, 6, 126-132.   | 3.3  | 3         |

| #    | ARTICLE  | IF   | CITATIONS |
|------|--|------|-----------|
| 1117 | Heart failure therapyâ€”technology to the fore. <i>Nature Reviews Cardiology</i> , 2012, 9, 73-74.   | 13.7 | 3         |
| 1118 | DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1029.   | 2.8  | 3         |
| 1119 | Corrigendum to â€œAnalysing recurrent hospitalizations in heart failure: a review ofÂstatistical methodology, with application toÂCHARM-Preservedâ€™ [Eur J Heart Fail2014;16:33-40]. <i>European Journal of Heart Failure</i> , 2014, 16, 592-592.                                    | 7.1  | 3         |
| 1120 | Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 295-301.  | 2.6  | 3         |
| 1121 | Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 41-48.   | 4.1  | 3         |
| 1122 | Prevalence and profile of â€œseasonal frequent flyersâ€•with chronic heart disease: Analysis of 1598 patients and 4588 patient-years follow-up. <i>International Journal of Cardiology</i> , 2019, 279, 126-132.   | 1.7  | 3         |
| 1123 | Angiotensin receptorâ€“neprilysin inhibition in heart failure with preserved ejection fraction: lessons from <sc>PARAGONâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 1525-1530.   | 7.1  | 3         |
| 1124 | Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2021, 110, 1308-1320.   | 3.3  | 3         |
| 1125 | Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008075.   | 3.9  | 3         |
| 1126 | Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53.                          | 2.7  | 3         |
| 1127 | Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. <i>PLoS ONE</i> , 2021, 16, e0255364.  | 2.5  | 3         |
| 1128 | Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 127-131. | 1.0  | 3         |
| 1129 | Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10â€year followâ€up of the Eplerenone Remodelling in Myocardial Infarction without Heart Failure trial. <i>European Journal of Heart Failure</i> , 2022, 24, 393-395.        | 7.1  | 3         |
| 1130 | Clinical characteristics and survival in patients with heart failure experiencing in hospital cardiac arrest. <i>Scientific Reports</i> , 2022, 12, 5685.  | 3.3  | 3         |
| 1131 | Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. <i>ESC Heart Failure</i> , 2022, 9, 2997-3008.   | 3.1  | 3         |
| 1132 | Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. <i>Diabetes Care</i> , 2022, 45, 2152-2155.  | 8.6  | 3         |
| 1133 | Atrial Natriuretic Factor Attenuates Prostaglandin E2-Stimulated Plasma Renin Activity in Humans. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 14, 326-330.   | 1.9  | 2         |
| 1134 | Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course. <i>International Journal of Cardiology</i> , 1991, 31, 295-303.  | 1.7  | 2         |

| #    | ARTICLE  | IF   | CITATIONS |
|------|--|------|-----------|
| 1135 | Acute heart failure: a practical guide to management. British Journal of Hospital Medicine, 2000, 61, 725-729.   | 0.2  | 2         |
| 1136 | Amlodipine for all undergoing PCI? The evidence is unconvincing. International Journal of Cardiology, 2002, 84, 30-32.   | 1.7  | 2         |
| 1137 | 17ÅŸ Oestradiol Does Not Attenuate the Response to Angiotensin I and II During Long Term Therapy in Postmenopausal Women. Cardiovascular Drugs and Therapy, 2004, 18, 31-36.   | 2.6  | 2         |
| 1138 | Ximelagatran Compared with Warfarin for the Prevention of Systemic Embolism and Stroke. An Imputed Placebo Analysis. Cardiovascular Drugs and Therapy, 2005, 19, 149-151.  | 2.6  | 2         |
| 1139 | The role of angiotensin II receptor blockers in the management of heart failure. Country Review Ukraine, 2005, 7, J10-J14.   | 0.8  | 2         |
| 1140 | Chilling Findings: The Need for Winter Vigilance in Heart Failure. Journal of Cardiac Failure, 2006, 12, 120-121.  | 1.7  | 2         |
| 1141 | Microvolt T-Wave Alternans Testing Has No Role at Present in Guiding Therapy for Patients at High Risk of Ventricular Arrhythmias. Journal of the American College of Cardiology, 2012, 59, 856.   | 2.8  | 2         |
| 1142 | Aliskiren in Type 2 Diabetes and Cardiorenal End Points. New England Journal of Medicine, 2013, 368, 1064-1066.  | 27.0 | 2         |
| 1143 | Response to Letter Regarding Article, "Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction". Circulation: Heart Failure, 2013, 6, e58.   | 3.9  | 2         |
| 1144 | Acute heart failure: have we got it all wrong?. European Journal of Heart Failure, 2014, 16, 1263-1267.  | 7.1  | 2         |
| 1145 | Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 2014, 16, 1265-1268.   | 4.4  | 2         |
| 1146 | Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials". Circulation, 2015, 132, e358. | 1.6  | 2         |
| 1147 | Trials and the "real world" - how different are they?. European Journal of Heart Failure, 2016, 18, 411-413.   | 7.1  | 2         |
| 1148 | Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. Journal of the American Heart Association, 2017, 6, .  | 3.7  | 2         |
| 1149 | PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 2019, 115, e136-e139.  | 3.8  | 2         |
| 1150 | Urinalysis. JACC: Heart Failure, 2019, 7, 402-403.   | 4.1  | 2         |
| 1151 | <sc>VICTORIA</sc> in context. European Journal of Heart Failure, 2020, 22, 1747-1751.  | 7.1  | 2         |
| 1152 | Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. European Heart Journal, 2021, 42, e5-e7.   | 2.2  | 2         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1153 | Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .  | 1.5 | 2         |
| 1154 | Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 2022, 9, 3655-3658.  | 3.1 | 2         |
| 1155 | The place of ACE inhibitors in the current treatment of chronic heart failure. Postgraduate Medical Journal, 1988, 64, 653-655.   | 1.8 | 1         |
| 1156 | The Place of Angiotensin-Converting Enzyme Inhibitors in Internal Medicine. Medical Principles and Practice, 1989, 1, 65-70.  | 2.4 | 1         |
| 1157 | Neurohumoral aspects of heart failure. Current Opinion in Cardiology, 1989, 4, 355-359.   | 1.8 | 1         |
| 1158 | Impaired vascular responsiveness to nitric oxide in renal transplant recipients. Transplantation Proceedings, 1999, 31, 304-305.  | 0.6 | 1         |
| 1159 | Why we Need New Strategies in CHF Management. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 12-16.  | 1.7 | 1         |
| 1160 | Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 131-136.                                 | 1.7 | 1         |
| 1161 | Older and more complicated heart failure patients: an increasing challenge to the health care system!. Coronary Health Care, 2001, 5, 121-125.  | 0.4 | 1         |
| 1162 | Drug Safety in Cardiovascular Disease: A Call to ACTION. Cardiovascular Drugs and Therapy, 2006, 20, 9-10.  | 2.6 | 1         |
| 1163 | Heart failure: are we neglecting the silent majority?. European Heart Journal, 2007, 28, 1047-1048.   | 2.2 | 1         |
| 1164 | Pathogenesis of Atherosclerosis and Vascular Disease in Type 2 Diabetes. , 0, , 16-36.  |     | 1         |
| 1165 | Prevention of Diabetes as a Means of Preventing Cardiovascular Disease. , 0, , 240-257.   |     | 1         |
| 1166 | Diabetes for Cardiologists. , 0, , 258-279.   |     | 1         |
| 1167 | Response to Letter Regarding Article, "Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure". Circulation, 2008, 118, .   | 1.6 | 1         |
| 1168 | Dual Renin-Angiotensin System Blockade in Heart Failure. Journal of the American College of Cardiology, 2009, 54, 278.  | 2.8 | 1         |
| 1169 | Event Rates in Trials of Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2010, 303, 732.   | 7.4 | 1         |
| 1170 | Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. European Journal of Heart Failure, 2010, 12, 416-416. | 7.1 | 1         |



| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1171 | Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study. <i>Journal of Clinical Hypertension</i> , 2012, 14, 731-731.                               | 2.0  | 1         |
| 1172 | Response to Letter Regarding Article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation". <i>Circulation</i> , 2014, 129, e21-2. | 1.6  | 1         |
| 1173 | Treatment of severe hypertriglyceridaemia. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 860.   | 11.4 | 1         |
| 1174 | End of the Road for Vagus Nerve Stimulation? —. <i>Journal of the American College of Cardiology</i> , 2016, 68, 159-160.   | 2.8  | 1         |
| 1175 | Disease Management Programs in Cardiology. <i>Circulation</i> , 2016, 133, 1836-1837.   | 1.6  | 1         |
| 1176 | Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.  | 5.5  | 1         |
| 1177 | CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: INSIGHTS FROM PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 734.             | 2.8  | 1         |
| 1178 | Effect of Omecamtiv Mecarbil in Patients with Ischemic and Non-Ischemic Heart Failure with Reduced Ejection Fraction: Results From COSMIC-HF. <i>Journal of Cardiac Failure</i> , 2017, 23, S11.  | 1.7  | 1         |
| 1179 | Reply. <i>JACC: Heart Failure</i> , 2017, 5, 852-853.   | 4.1  | 1         |
| 1180 | Risk stratification according to insulin type: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1498-1498.   | 7.1  | 1         |
| 1181 | Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. <i>ESC Heart Failure</i> , 2018, 5, 1052-1059.   | 3.1  | 1         |
| 1182 | EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 691.   | 2.8  | 1         |
| 1183 | Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 175.  | 6.8  | 1         |
| 1184 | Diagnosing heart failure with preserved ejection fraction—What's the score?. <i>European Journal of Heart Failure</i> , 2020, 22, 425-427.  | 7.1  | 1         |
| 1185 | MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .   | 0.7  | 1         |
| 1186 | Gender- and Age-Specific Rates of Heart Failure and other Adverse Cardiovascular Outcomes in Systemic Sclerosis. <i>Rheumatology</i> , 2022, , .  | 1.9  | 1         |
| 1187 | Current management of heart failure. <i>Practitioner</i> , 2002, 246, 438-43.   | 0.3  | 1         |
| 1188 | Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes. <i>Clinical Research in Cardiology</i> , 2022, , 1.   | 3.3  | 1         |

| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1189 | An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. <i>Kidney International Reports</i> , 2022, , .   | 0.8  | 1         |
| 1190 | Epidemiology of Vascular Disease in Diabetes. , 0, , 1-15.  |      | 0         |
| 1191 | The BP response to the first dose of captopril: Does the dose size matter and does it predict the BP response to subsequent doses?. <i>Journal of Molecular and Cellular Cardiology</i> , 1990, 22, S95.  | 1.9  | 0         |
| 1192 | Silent myocardial ischemia: A critical appraisal. <i>International Journal of Cardiology</i> , 1991, 33, 182.   | 1.7  | 0         |
| 1193 | Comparison of the effects of ANF 99â€™126 and ANF 103â€™126 on captoprilâ€™induced renin release in man. <i>Clinical Endocrinology</i> , 1991, 34, 493-499.   | 2.4  | 0         |
| 1194 | Digoxin for patients with heart failure in sinus rhythm. <i>Lancet</i> , The, 1997, 350, 519.   | 13.7 | 0         |
| 1195 | Prescribing and emergency admissions for heart failure in greater glasgow. <i>Journal of Cardiac Failure</i> , 1999, 5, 3-7.  | 1.7  | 0         |
| 1196 | Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme. <i>Blood Pressure</i> , 2000, 9, 60-60.  | 1.5  | 0         |
| 1197 | Review: Optimising the use of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005, 6, S2-S5.  | 1.7  | 0         |
| 1198 | ¿CuÃ¡l deberÃa ser el fÃ¡rmaco que se aÃ±adiera a un IECA y un bloqueador beta en la insuficiencia cardiaca por disfunciÃ³n sistÃ³lica: un antagonista de la aldosterona o un ARA-II? Evidencias clÃnicas con ambos. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006, 6, 29C-36C. | 0.2  | 0         |
| 1199 | Response to Letter Regarding Article, â€œEffect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomasâ€. <i>Circulation</i> , 2007, 115, .  | 1.6  | 0         |
| 1200 | Diabetes and Peripheral Arterial Disease. , 0, , 199-222.   |      | 0         |
| 1201 | Diabetes and Hypertension. , 0, , 135-174.  |      | 0         |
| 1202 | Coronary Heart Disease and Diabetes. , 0, , 37-67.  |      | 0         |
| 1203 | Diabetes and Acute Coronary Syndromes. , 0, , 69-92.  |      | 0         |
| 1204 | Corrigendum to â€œEffects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blockerâ€[ <i>European Journal of Heart Failure</i> 9/4 (2007) 429-434]. <i>European Journal of Heart Failure</i> , 2007, 9, 1074-1074.                              | 7.1  | 0         |
| 1205 | Study Acronyms. , 0, , 280-286.   |      | 0         |
| 1206 | Diabetes, Left Ventricular Systolic Dysfunction and Chronic Heart Failure. , 0, , 93-134.   |      | 0         |

| #    | ARTICLE  | IF   | CITATIONS |
|------|--|------|-----------|
| 1207 | Diabetes and Stroke / Transient Ischaemic Attacks. , 0, , 175-198.   |      | 0         |
| 1208 | Prevention of Cardiovascular Events in Diabetic Patients. , 0, , 223-239.  |      | 0         |
| 1209 | Health Related Quality of Life in I-PRESERVE Trial. Journal of Cardiac Failure, 2008, 14, S73.   | 1.7  | 0         |
| 1210 | Response to The J-Point Revisited. Hypertension, 2008, 51, .   | 2.7  | 0         |
| 1211 | Medical management of advanced heart failure. Progress in Palliative Care, 2008, 16, 229-240.  | 1.2  | 0         |
| 1212 | Should beta-blockade continue to be withheld from patients with chronic heart failure and asthma?: reply. European Heart Journal, 2009, 30, 1287-1288.   | 2.2  | 0         |
| 1213 | Heart failure and chronic obstructive pulmonary disease: lung function test interpretation: reply. European Journal of Heart Failure, 2009, 11, 632-633.   | 7.1  | 0         |
| 1214 | Corrigendum to "Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial" [Eur J Heart Fail 2009;11:795-801]. European Journal of Heart Failure, 2010, 12, 765-765. | 7.1  | 0         |
| 1215 | Hospital-at-home care for CHF-verdict, 'not proven'. Nature Reviews Cardiology, 2010, 7, 63-64.  | 13.7 | 0         |
| 1216 | Acute ischemic events in HF-should we include sudden death?. Nature Reviews Cardiology, 2011, 8, 192-193.  | 13.7 | 0         |
| 1217 | Response to Letter Regarding Article, "Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both", Circulation, 2011, 123, .                           | 1.6  | 0         |
| 1218 | Response to Letters Regarding Article, "Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction", Circulation, 2012, 126, .  | 1.6  | 0         |
| 1219 | Feasibility/eligibility of T-wave alternans testing in patients with heart failure: should we rethink our current modus operandi?: reply. European Journal of Heart Failure, 2012, 14, 676-677.  | 7.1  | 0         |
| 1220 | Microvolt T-wave alternans testing should be used to guide arrhythmic therapy in heart failure patients: reply. European Journal of Heart Failure, 2012, 14, 678-678.  | 7.1  | 0         |
| 1221 | Reply to the letter by Dr Erqou regarding "Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients", American Heart Journal, 2012, 163, e37.   | 2.7  | 0         |
| 1222 | Reply. Journal of the American College of Cardiology, 2013, 61, 1749.  | 2.8  | 0         |
| 1223 | Letter by MacDonald et al Regarding Article, "Catheter Ablation of Atrial Fibrillation". Circulation, 2013, 127, e433.   | 1.6  | 0         |
| 1224 | Microvolt T-wave alternans testing in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 2014, 16, 113-113.   | 7.1  | 0         |

|      |  |     |   |
|------|--|-----|---|
| 1225 | Reply. Journal of the American College of Cardiology, 2014, 64, 1535-1536.   | 2.8 | 0 |
| 1226 | The Clinical Implications of Cardiac Troponin I Measured by an “Ultrasensitive” Assay in Acute Decompensated Heart Failure: Insights from ASCEND-HF. Journal of Cardiac Failure, 2015, 21, S25-S26.      | 1.7 | 0 |
| 1227 | Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction. Journal of Cardiac Failure, 2016, 22, S65-S66. | 1.7 | 0 |
| 1228 | Target Dose of Sacubitril/Valsartan Achieved in Most Patients with HFrEF Irrespective of Baseline SBP. Journal of Cardiac Failure, 2016, 22, S66.  | 1.7 | 0 |
| 1229 | Sacubitril/Valsartan Associated with Lower Declines in Health-Related Quality of Life Compared with Enalapril in Patients with Heart Failure Hospitalization. Journal of Cardiac Failure, 2016, 22, S24. | 1.7 | 0 |
| 1230 | Improved Contractility and Evolution of Ventricular Remodelling Through Time in the Chronic Oral   |     |   |

| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1243 | Reply. JACC: Heart Failure, 2020, 8, 597-598.   | 4.1  | 0         |
| 1244 | Dyslipidaemia, a factor worthy of adjustment: reply. European Journal of Heart Failure, 2020, 22, 564-565.  | 7.1  | 0         |
| 1245 | Reply. Journal of the American College of Cardiology, 2020, 75, 1501-1502.  | 2.8  | 0         |
| 1246 | Considering dose in pharmacological therapies for heart failure – Authors' reply. Lancet, The, 2021, 397, 275.  | 13.7 | 0         |
| 1247 | Sacubitril / valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide?. Kardiologia Polska, 2021, 79, 104-105.  | 0.6  | 0         |
| 1248 | Reply. Journal of the American College of Cardiology, 2021, 78, 760-761.  | 2.8  | 0         |
| 1249 | Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. Journal of Cardiac Failure, 2021, 27, 1027-1030.  | 1.7  | 0         |
| 1250 | Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart, 2001, 86, 97-103.   | 2.9  | 0         |
| 1251 | Clinical assessment and investigation of patients with suspected heart failure. , 2004, , 75-91.  |      | 0         |
| 1252 | Discharge rates for suspected acute coronary syndromes: Authors' reply. BMJ: British Medical Journal, 2004, 329, 173.2.   | 2.3  | 0         |
| 1253 | Heart Failure – Optimal Pharmacological Therapy. , 2008, , 49-74.   |      | 0         |
| 1254 | The year in cardiology 2019: heart failure. Revista Romana De Cardiologie, 2020, 30, 185-204.   | 0.1  | 0         |
| 1255 | Age-Adjusted Survival Extrapolations – Results May Differ From Those Generated by the Weibull Model – Reply. JAMA Cardiology, 2022, , .   | 6.1  | 0         |
| 1256 | Can an implanted minipump deliver for diabetes patients?. Nature Medicine, 2022, 28, 27-28.   | 30.7 | 0         |
| 1257 | FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose. Nephrology Dialysis Transplantation, 2022, 37, . | 0.7  | 0         |